Treatment    O
with    O
Rho    O
-    O
kinase    O
inhibitor    O
Y-27632    B-Pyridine114692510
reduces    O
the    O
size    O
of    O
the    O
particle    O
,    O
and    O
it    O
is    O
extremely    O
mechanosensitive    O
.    O

Treatment    O
to    O
slow    O
down    O
the    O
progression    O
of    O
the    O
disease    O
may    O
include    O
nintedanib    O
or    O
pirfenidone    B-Pyridine114692510
.    O

A    O
Cochrane    O
review    O
comparing    O
pirfenidone    B-Pyridine114692510
with    O
placebo    O
,    O
found    O
a    O
reduced    O
risk    O
of    O
disease    O
progression    O
by    O
30%    O
.    O

ABT-202    B-Pyridine114692510

Nornicotine    B-Pyridine114692510
is    O
an    O
alkaloid    O
found    O
in    O
various    O
plants    O
including    O
"    O
Nicotiana    O
"    O
,    O
the    O
tobacco    O
plant    O
.    O

Nornicotine    B-Pyridine114692510

The    O
Ariva    O
brand    O
has    O
been    O
shown    O
to    O
have    O
significantly    O
reduced    O
levels    O
of    O
tobacco    O
-    O
specific    O
lung    O
carcinogen    O
4-(methylnitrosamino)-l-(3-pyridyl)-l    O
-    O
butanone    O
(    O
NNK    B-Pyridine114692510
)    O
although    O
"    O
exposures    O
to    O
other    O
tobacco    O
-    O
specific    O
nitrosamines    O
(    O
i.e.    O
,    O
NNN    B-Pyridine114692510
)    O
,    O
polycyclic    O
aromatic    O
hydrocarbons    O
(    O
e.g.    O
,    O
benzo[a]pyrene    O
)    O
,    O
and    O
metals    O
"    O
have    O
not    O
been    O
assessed    O
.    O

mangafodipir    B-Pyridine114692510
(    O
INN    O
)    O

lornoxicam    B-Pyridine114692510

Bearers    O
of    O
this    O
SNP    O
may    O
or    O
may    O
not    O
show    O
increased    O
risk    O
of    O
developing    O
acute    O
gastrointestinal    O
bleeding    O
during    O
the    O
use    O
of    O
non    O
-    O
steroidal    O
anti    O
-    O
inflammatory    O
drugs    O
(    O
NSAIDs    O
)    O
that    O
are    O
its    O
substrates    O
such    O
as    O
aceclofenac    O
,    O
celecoxib    O
,    O
diclofenac    O
,    O
ibuprofen    O
,    O
indomethacin    O
,    O
lornoxicam    B-Pyridine114692510
,    O
meloxicam    O
,    O
naproxen    O
,    O
piroxicam    O
,    O
tenoxicam    B-Pyridine114692510
,    O
and    O
valdecoxib    O
.    O

Ferroin    B-Pyridine114692510
is    O
the    O
chemical    O
compound    O
with    O
the    O
formula    O
[    O
Fe("o    O
"-    O
phen)3]SO4    O
,    O
where    O
"    O
o    O
"-    O
phen    O
is    O
an    O
abbreviation    O
for    O
phenanthroline    B-Pyridine114692510
,    O
a    O
bidentate    O
ligand    O
.    O

EMC1    O
,    O
also    O
known    O
as    O
KIAA0090    O
,    O
contains    O
a    O
single    O
TMD    O
(    O
aa    O
959    O
-    O
979    O
)    O
and    O
Pyrroloquinoline    B-Pyridine114692510
quinone    I-Pyridine114692510
(    O
PQQ)-like    O
repeats    O
(    O
aa    O
21    O
-    O
252    O
)    O
,    O
which    O
could    O
form    O
a    O
β-propeller    O
domain    O
.    O

Pyrroloquinoline    B-Pyridine114692510
quinone    I-Pyridine114692510
(    O
PQQ    O
)    O
,    O
a    O
redox    O
cofactor    O
and    O
controversial    O
nutritional    O
supplement    O

Pyrroloquinoline    B-Pyridine114692510
quinone    I-Pyridine114692510
(    O
PQQ    B-Pyridine114692510
)    O
is    O
redox    O
cofactor    O
.    O

:    O
N06AF02    O
Nialamide    B-Pyridine114692510

Nialamide    B-Pyridine114692510

lazabemide    B-Pyridine114692510
(    O
INN    O
)    O

The    O
active    O
ingredient    O
was    O
changed    O
when    O
it    O
was    O
renamed    O
in    O
1959    O
to    O
be    O
the    O
laxative    O
bisacodyl    B-Pyridine114692510
.    O

Carter    O
's    O
Little    O
Liver    O
Pills    O
predated    O
the    O
other    O
available    O
forms    O
of    O
bisacodyl    B-Pyridine114692510
and    O
was    O
a    O
very    O
popular    O
and    O
heavily    O
advertised    O
patent    O
medicine    O
up    O
until    O
the    O
1960s    O
,    O
spawning    O
a    O
common    O
saying    O
(    O
with    O
variants    O
)    O
in    O
the    O
first    O
half    O
of    O
the    O
20th    O
century    O
:    O
"    O
He    O
/    O
She    O
has    O
more    O
than    O
Carter    O
has    O
Little    O
Liver    O
Pills    O
"    O
.    O

In    O
the    O
U.S.    O
,    O
dioctyl    O
sodium    O
sulfosuccinate    O
is    O
available    O
under    O
multiple    O
brand    O
names    O
:    O
Aqualax    O
,    O
Calube    O
,    O
Colace    O
,    O
Colace    O
Micro    O
-    O
Enema    O
,    O
Correctol    O
Softgel    O
Extra    O
Gentle    O
,    O
DC-240    O
,    O
Dialose    O
,    O
Diocto    O
,    O
Dioctocal    O
,    O
Dioctosoftez    O
,    O
Dioctyn    O
,    O
Dionex    O
,    O
Doc    O
-    O
Q    O
-    O
Lace    O
,    O
Docu    O
Soft    O
,    O
Docucal    O
,    O
Doculax    O
,    O
Docusoft    O
S    O
,    O
DOK    O
,    O
DOS    O
,    O
Doss    O
-    O
Relief    O
,    O
DSS    O
,    O
Dulcolax    O
-    O
Stool    O
Softener    O
(    O
not    O
to    O
be    O
confused    O
with    O
another    O
drug    O
marketed    O
under    O
the    O
Dulcolax    O
brand    O
,    O
bisacodyl    B-Pyridine114692510
,    O
which    O
is    O
a    O
stimulant    O
laxative    O
)    O
,    O
Ex    O
-    O
Lax    O
Stool    O
Softener    O
,    O
Fleet    O
Sof    O
-    O
Lax    O
,    O
Genasoft    O
,    O
Kasof    O
,    O
Laxa    O
-    O
basic    O
,    O
Modane    O
Soft    O
,    O
Octycine-100    O
,    O
Pedia    O
-    O
Lax    O
,    O
Preferred    O
Plus    O
Pharmacy    O
Stool    O
Softener    O
,    O
Regulax    O
SS    O
,    O
Sulfalax    O
Calcium    O
,    O
Sur    O
-    O
Q    O
-    O
Lax    O
,    O
Surfak    O
Stool    O
Softener    O
,    O
and    O
Therevac    O
-    O
SB    O
.    O

Sibopirdine    B-Pyridine114692510

Acrivastine    B-Pyridine114692510
is    O
a    O
medication    O
used    O
for    O
the    O
treatment    O
of    O
allergies    O
and    O
hay    O
fever    O
.    O

Ispronicline    B-Pyridine114692510
(    O
TC-1734    B-Pyridine114692510
,    O
AZD-3480    B-Pyridine114692510
)    O
is    O
an    O
experimental    O
drug    O
which    O
acts    O
as    O
a    O
partial    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

A-84543    B-Pyridine114692510
is    O
a    O
drug    O
developed    O
by    O
Abbott    O
,    O
which    O
acts    O
as    O
an    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
with    O
high    O
selectivity    O
for    O
the    O
α4β2    O
subtype    O
.    O

Resiquimod    B-Pyridine114692510

Isoxyl    O
inhibits    O
"    O
M.    O
bovis    O
"    O
with    O
six    O
hours    O
of    O
exposure    O
,    O
which    O
is    O
similar    O
to    O
isoniazid    O
and    O
ethionamide    B-Pyridine114692510
,    O
two    O
other    O
prominent    O
anti    O
-    O
TB    O
drugs    O
.    O

ethionamide    B-Pyridine114692510
(    O
INN    O
)    O

Ethionamide    B-Pyridine114692510

The    O
hydroxyl    O
group    O
was    O
then    O
oxidized    O
to    O
a    O
carbonyl    O
group    O
giving    O
ketone    O
6    O
by    O
action    O
of    O
pyridinium    B-Pyridine114692510
dichromate    I-Pyridine114692510
.    O

More    O
selective    O
or    O
gentler    O
oxidizing    O
reagents    O
include    O
pyridinium    B-Pyridine114692510
chlorochromate    I-Pyridine114692510
(    O
PCC    O
)    O
and    O
pyridinium    B-Pyridine114692510
dichromate    I-Pyridine114692510
(    O
PDC    O
)    O
.    O

Specific    O
therapy    O
for    O
treating    O
high    O
blood    O
pressure    O
(    O
e.g.    O
,    O
amlodipine    B-Pyridine114692510
)    O
,    O
should    O
be    O
added    O
if    O
necessary    O
.    O

For    O
example    O
,    O
calcium    O
channel    O
blockers    O
(    O
i.e.    O
diltiazem    O
,    O
amlodipine    B-Pyridine114692510
)    O
are    O
P    O
-    O
gp    O
substrates    O
and    O
can    O
lead    O
to    O
increased    O
concentrations    O
of    O
these    O
drugs    O
when    O
taken    O
with    O
simeprevir    O
.    O

Dr.    O
Reddy    O
’s    O
Para    O
4    O
application    O
strategy    O
for    O
generic    O
business    O
received    O
a    O
severe    O
setback    O
when    O
Reddy    O
’s    O
lost    O
the    O
patent    O
challenge    O
in    O
the    O
case    O
of    O
Pfizer    O
’s    O
drug    O
Norvasc    B-Pyridine114692510
(    O
amlodipine    B-Pyridine114692510
maleate    I-Pyridine114692510
)    O
,    O
a    O
drug    O
indicated    O
for    O
the    O
treatment    O
of    O
hypertension    O
and    O
angina    O
.    O

Some    O
of    O
these    O
calcium    O
antagonists    O
include    O
verapamil    O
,    O
diltiazem    O
,    O
amlodipine    B-Pyridine114692510
,    O
benidipine    O
,    O
cilnidipine    O
,    O
nicardipine    O
,    O
and    O
barnidipine    B-Pyridine114692510
.    O

Amlodipine    B-Pyridine114692510

:*    O
Amlodipin    O
Orion    O
(    O
"    O
amlodipine    B-Pyridine114692510
"    O
)    O

amlodipine    B-Pyridine114692510
(    O
calcium    O
channel    O
blocker    O
)    O

The    O
second    O
-    O
generation    O
H1-antihistamine    O
,    O
rupatadine    B-Pyridine114692510
,    O
was    O
found    O
to    O
significantly    O
reduce    O
the    O
development    O
of    O
chronic    O
cold    O
urticaria    O
symptom    O
without    O
an    O
increase    O
in    O
adverse    O
effects    O
using    O
20    O
and    O
40    O
mg    O
.    O

SIB-1893    B-Pyridine114692510

4-Nitropyridine-"N"-oxide    B-Pyridine114692510
is    O
a    O
chemical    O
compound    O
.    O

Therefore    O
,    O
insect    O
growth    O
regulators    O
,    O
such    O
as    O
buprofezin    O
and    O
pyriproxyfen    B-Pyridine114692510
,    O
conserve    O
natural    O
predators    O
,    O
as    O
opposed    O
to    O
conventional    O
insecticides    O
,    O
which    O
can    O
indiscriminately    O
kill    O
both    O
predator    O
and    O
prey    O
populations    O
.    O

To    O
combat    O
this    O
disease    O
,    O
insect    O
growth    O
regulator    O
(    O
IGR    O
)    O
,    O
pyriproxyfen    B-Pyridine114692510
has    O
been    O
used    O
.    O

Perampanel    B-Pyridine114692510

Ethosuximide    O
and    O
perampanel    B-Pyridine114692510
can    O
also    O
produce    O
euphoria    O
at    O
therapeutic    O
doses    O
.    O

NS-2710    B-Pyridine114692510

esomeprazole    B-Pyridine114692510

Proton    O
pump    O
inhibitors    O
,    O
e.g.    O
esomeprazole    B-Pyridine114692510

Esomeprazole    B-Pyridine114692510
sold    O
under    O
the    O
brand    O
name    O
Nexium    B-Pyridine114692510
(    O
or    O
Nexum    B-Pyridine114692510
)    O
among    O
others    O
,    O
is    O
a    O
proton    O
-    O
pump    O
inhibitor    O
which    O
reduces    O
stomach    O
acid    O
.    O

Proton    O
pump    O
inhibitors    O
(    O
PPIs    O
)    O
:    O
The    O
PPIs    O
include    O
omeprazole    O
(    O
Prilosec    O
,    O
Losec    O
)    O
,    O
lansoprazole    O
(    O
Prevacid    O
)    O
,    O
rabeprazole    B-Pyridine114692510
(    O
Aciphex    O
)    O
,    O
pantoprazole    B-Pyridine114692510
(    O
Protonix    O
,    O
Pantoloc    O
)    O
,    O
and    O
esomeprazole    B-Pyridine114692510
(    O
Nexium    O
)    O
.    O

Esomeprazole    B-Pyridine114692510
(    O
brand    O
names    O
:    O
Nexium    O
,    O
Esotrex    O
,    O
Emanera    O
,    O
Neo    O
-    O
Zext    O
)    O

2-Aminopyridine    B-Pyridine114692510

Nicoracetam    B-Pyridine114692510
is    O
a    O
drug    O
from    O
the    O
racetam    O
family    O
.    O

Norbormide    B-Pyridine114692510
(    O
Raticate    B-Pyridine114692510
,    O
Shoxin    B-Pyridine114692510
)    O
is    O
a    O
toxic    O
compound    O
used    O
as    O
a    O
rodenticide    O
.    O

In    O
osteoporosis    O
and    O
Paget    O
's    O
,    O
the    O
most    O
popular    O
first    O
-    O
line    O
bisphosphonate    O
drugs    O
are    O
alendronate    O
and    O
risedronate    B-Pyridine114692510
.    O

Risedronate    B-Pyridine114692510
(    O
Actonel    O
)    O
—    O
2000    O

FPPS    O
is    O
the    O
target    O
of    O
bisphosphonate    O
drugs    O
such    O
as    O
Fosamax    O
(    O
alendronate    O
)    O
and    O
Actonel    O
(    O
risedronate    B-Pyridine114692510
)    O
.    O

Etidronate    O
has    O
the    O
same    O
disadvantage    O
as    O
pyrophosphate    O
in    O
inhibiting    O
mineralization    O
,    O
but    O
all    O
of    O
the    O
potent    O
"    O
N    O
"-    O
containing    O
bisphosphonates    O
including    O
Alendronate    O
and    O
also    O
risedronate    B-Pyridine114692510
,    O
ibandronate    O
,    O
and    O
zoledronate    O
,    O
do    O
not    O
.    O

Atevirdine    B-Pyridine114692510
—    O
antiretroviral    O

Ilaprazole    B-Pyridine114692510
is    O
a    O
proton    O
pump    O
inhibitor    O
developed    O
by    O
Ilyang    O
Pharmaceutical    O
to    O
treat    O
dyspepsia    O
,    O
peptic    O
ulcer    O
disease    O
,    O
gastroesophageal    O
reflux    O
disease    O
,    O
and    O
duodenal    O
ulcer    O
.    O

Due    O
to    O
its    O
broad    O
scope    O
,    O
the    O
Kröhnke    O
method    O
has    O
seen    O
wide    O
applicability    O
to    O
for    O
the    O
synthesis    O
of    O
bipyridine    B-Pyridine114692510
(    O
16    O
)    O
,    O
terpyridine    B-Pyridine114692510
(    O
17    O
)    O
,    O
quaterpyridines    O
(    O
18    O
)    O
and    O
even    O
up    O
to    O
septipyridines    O
(    O
19    O
)    O
as    O
shown    O
below    O
.    O

The    O
Kröhnke    O
methodology    O
has    O
also    O
been    O
utilized    O
to    O
generate    O
a    O
number    O
of    O
interesting    O
metal    O
-    O
binding    O
ligands    O
since    O
polypyridyl    O
complexes    O
such    O
as    O
bipyridine    B-Pyridine114692510
(    O
bipy    O
)    O
have    O
been    O
used    O
extensively    O
as    O
ligands    O
.    O

The    O
complexation    O
of    O
bipyridine    B-Pyridine114692510
or    O
tripyridines    O
with    O
ruthenium    O
,    O
silver    O
or    O
other    O
metal    O
ions    O
is    O
of    O
great    O
utility    O
in    O
the    O
construction    O
of    O
complex    O
architectures    O
of    O
many    O
individual    O
molecules    O
.    O

:    O
N05AX07    O
Prothipendyl    B-Pyridine114692510

Pyridostigmine    B-Pyridine114692510

Myasthenia    O
gravis    O
is    O
generally    O
treated    O
with    O
medications    O
known    O
as    O
acetylcholinesterase    O
inhibitors    O
such    O
as    O
neostigmine    O
and    O
pyridostigmine    B-Pyridine114692510
.    O

Pyridostigmine    B-Pyridine114692510
is    O
a    O
relatively    O
long    O
-    O
acting    O
drug    O
(    O
when    O
compared    O
to    O
other    O
cholinergic    O
agonists    O
)    O
,    O
with    O
a    O
half    O
-    O
life    O
around    O
four    O
hours    O
with    O
relatively    O
few    O
side    O
effects    O
.    O

In    O
the    O
1960s    O
smaller    O
scale    O
experiments    O
took    O
place    O
with    O
non    O
-    O
lethal    O
agents    O
such    O
as    O
LSD    O
and    O
glycollates    O
,    O
and    O
more    O
recently    O
testing    O
focused    O
on    O
countermeasures    O
such    O
as    O
pyridostigmine    B-Pyridine114692510
bromide    I-Pyridine114692510
which    O
is    O
a    O
pre    O
-    O
treatment    O
for    O
nerve    O
agents    O
.    O

:*    O
Disomet    O
(    O
"    O
disopyramide    B-Pyridine114692510
"    O
)    O

Disopyramide    B-Pyridine114692510

Class    O
Ia    O
—    O
Fast    O
sodium    O
channels    O
(    O
quinidine    O
,    O
ajmaline    O
,    O
procainamide    O
,    O
disopyramide    B-Pyridine114692510
)    O

Phenampromide    O
is    O
an    O
opioid    O
analgesic    O
from    O
the    O
ampromide    O
family    O
of    O
drugs    O
,    O
related    O
to    O
other    O
drugs    O
such    O
as    O
propiram    B-Pyridine114692510
and    O
diampromide    O
.    O

Diampromide    O
is    O
an    O
opioid    O
analgesic    O
from    O
the    O
ampromide    O
family    O
of    O
drugs    O
,    O
related    O
to    O
other    O
drugs    O
such    O
as    O
propiram    B-Pyridine114692510
.    O

Its    O
cardiovascular    O
safety    O
profile    O
compares    O
favorably    O
with    O
that    O
of    O
rosiglitazone    B-Pyridine114692510
,    O
which    O
was    O
withdrawn    O
from    O
some    O
markets    O
after    O
concerns    O
about    O
an    O
increased    O
risk    O
of    O
cardiac    O
events    O
.    O

A    O
press    O
release    O
by    O
GlaxoSmithKline    O
in    O
February    O
2007    O
noted    O
that    O
there    O
is    O
a    O
greater    O
incidence    O
of    O
fractures    O
of    O
the    O
upper    O
arms    O
,    O
hands    O
and    O
feet    O
in    O
female    O
diabetics    O
given    O
rosiglitazone    B-Pyridine114692510
compared    O
with    O
those    O
given    O
metformin    O
or    O
glyburide    O
.    O

In    O
clinical    O
trials    O
,    O
a    O
certain    O
insulin    O
sensitizer    O
called    O
"    O
rosiglitazone    B-Pyridine114692510
"    O
improved    O
cognition    O
in    O
a    O
subset    O
of    O
AD    O
patients    O
;    O

Among    O
the    O
strategies    O
that    O
have    O
been    O
explored    O
to    O
minimize    O
such    O
side    O
effects    O
are    O
intermittent    O
treatment    O
regimens    O
and    O
combinations    O
with    O
insulin    O
sentitizers    O
(    O
rosiglitazone    B-Pyridine114692510
)    O
or    O
antidiabetics    O
(    O
metformin    O
)    O
to    O
prevent    O
metabolic    O
dysfunction    O
.    O

According    O
to    O
Zeev    O
Vlodaver    O
,    O
Robert    O
F.    O
Wilson    O
and    O
Daniel    O
J.    O
Garry    O
,    O
"    O
exenatide    O
and    O
liraglutide    O
are    O
synthetic    O
GLP-1    O
agonists    O
and    O
have    O
demonstrated    O
glycemic    O
efficacy    O
(    O
HbA1c    O
reductions    O
of    O
between    O
0.7    O
and    O
2%    O
)    O
associated    O
with    O
mild    O
weight    O
loss    O
.    O
"    O
Glyburide    O
,    O
metformin    O
and    O
rosiglitazone    B-Pyridine114692510
have    O
been    O
assessed    O
as    O
a    O
monotherapy    O
in    O
the    O
durability    O
of    O
glycemic    O
efficacy    O
.    O

Dimethindene    B-Pyridine114692510
-    O
N    O
,    O
N    O
-    O
Dimethyl-3-[(1S)-1-(2-pyridinyl)ethyl]-1H    O
-    O
indene-2-ethanamine    O
,    O
CAS    O
#    O
121367    O
-    O
05    O
-    O
3    O
,    O
mixed    O
M2    O
/    O
histamine    O
H1    O
antagonist    O

dimetindene    B-Pyridine114692510
(    O
INN    O
)    O

The    O
thiolate    O
anion    O
can    O
be    O
formed    O
by    O
reaction    O
with    O
sodium    O
carbonate    O
,    O
and    O
zinc    B-Pyridine114692510
pyrithione    I-Pyridine114692510
is    O
formed    O
when    O
zinc    O
chloride    O
is    O
added    O
.    O

In    O
2011    O
,    O
several    O
compounds    O
(    O
antifungals    O
,    O
fungicides    O
,    O
and    O
biocides    O
)    O
where    O
shown    O
to    O
effectively    O
inhibit    O
the    O
growth    O
of    O
"    O
P.    O
destructans    O
"    O
including    O
benzalkonium    O
chloride    O
,    O
chloroacetoxyquinoline    O
,    O
chloroxine    O
,    O
ciclopirox    O
olamine    O
,    O
econazole    O
,    O
phenylmercuric    O
acetate    O
,    O
pyrithione    B-Pyridine114692510
zinc    I-Pyridine114692510
and    O
sulconazole    O
.    O

The    O
application    O
of    O
antifungal    O
shampoos    O
such    O
as    O
pyrithione    B-Pyridine114692510
zinc    I-Pyridine114692510
,    O
formaldehyde    O
and    O
salicylic    O
acid    O
is    O
effective    O
against    O
black    O
piedra    O
.    O

While    O
cytostatic    O
agents    O
such    O
as    O
zinc    B-Pyridine114692510
pyrithione    I-Pyridine114692510
are    O
first    O
line    O
,    O
keratolytics    O
(    O
salicylic    O
acid    O
and    O
sulfur    O
)    O
can    O
also    O
be    O
used    O
in    O
the    O
treatment    O
of    O
dandruff    O
and    O
seborrheic    O
dermatitis    O
.    O

dabigatran    B-Pyridine114692510
(    O
USAN    O
)    O

Dabigatran    B-Pyridine114692510
vs.    O
warfarin    O
for    O
stroke    O
prevention    O
with    O
non    O
-    O
valvular    O
atrial    O
fibrillation    O
(    O
English    O
)    O

Other    O
drugs    O
with    O
adverse    O
reactions    O
include    O
adefovir    O
,    O
dabigatran    B-Pyridine114692510
etexilate    I-Pyridine114692510
,    O
lamivudine    O
,    O
and    O
vincristine    O
.    O

These    O
direct    O
Factor    O
Xa    O
inhibitors    O
can    O
be    O
administered    O
orally    O
,    O
as    O
can    O
dabigatran    B-Pyridine114692510
etexilate    I-Pyridine114692510
which    O
is    O
a    O
direct    O
thrombin    O
inhibitor    O
.    O

UB-165    B-Pyridine114692510
,    O
a    O
nAChR    O
agonist    O
of    O
a    O
subtype    O
with    O
a    O
function    O
leading    O
to    O
release    O
of    O
dopamine    O
and    O
noradrenaline    O
in    O
the    O
brain    O
.    O

2,6-Diacetylpyridine    B-Pyridine114692510
is    O
an    O
organic    O
compound    O
with    O
the    O
formula    O
C5H3N(C(O)CH3)2    O
.    O

nicorandil    B-Pyridine114692510

Common    O
examples    O
are    O
alendronate    O
(    O
a    O
bisphosphonate    O
,    O
commonly    O
prescribed    O
for    O
osteoporosis    O
)    O
,    O
cytotoxic    O
drugs    O
(    O
e.g.    O
methotrexate    O
,    O
i.e.    O
chemotherapy    O
)    O
,    O
non    O
-    O
steroidal    O
anti    O
-    O
inflammatory    O
drugs    O
,    O
nicorandil    B-Pyridine114692510
(    O
may    O
be    O
prescribed    O
for    O
angina    O
)    O
and    O
propylthiouracil    O
(    O
e.g.    O
used    O
for    O
hyperthyroidism    O
)    O
.    O

:    O
G01AX66    O
Octenidine    B-Pyridine114692510
,    O
combinations    O

:    O
C10AD01    O
Niceritrol    B-Pyridine114692510

2-Formylpyridine    B-Pyridine114692510
,    O
also    O
commonly    O
called    O
pyridine-2-carboxaldehyde    O
,    O
is    O
an    O
organic    O
compound    O
with    O
the    O
formula    O
NC5H4CHO    O
.    O

PPADS    B-Pyridine114692510
(    O
pyridoxalphosphate-6-azophenyl-2',4'-disulfonic    O
acid    O
)    O
is    O
a    O
selective    O
purinergic    O
P2X    O
antagonist    O
.    O

:    O
N06BX08    O
Pirisudanol    B-Pyridine114692510

Nicotinic    B-Pyridine114692510
acid    I-Pyridine114692510
adenine    I-Pyridine114692510
dinucleotide    I-Pyridine114692510
phosphate    I-Pyridine114692510
,    O
(    O
NAADP    B-Pyridine114692510
)    O
,    O
is    O
a    O
Ca2    O
+    O
-mobilizing    O
second    O
messenger    O
synthesised    O
in    O
response    O
to    O
extracellular    O
stimuli    O
.    O

Brooker's    B-Pyridine114692510
merocyanine    I-Pyridine114692510
(    O
1-methyl-4-[(oxocyclohexadienylidene)ethylidene]-1,4-dihydropyridine    O
,    B-Pyridine114692510
MOED    I-Pyridine114692510
)    O
is    O
an    O
organic    O
dye    O
belonging    O
to    O
the    O
class    O
of    O
merocyanines    O
.    O

Oximes    O
such    O
as    O
obidoxime    O
,    O
pralidoxime    B-Pyridine114692510
and    O
asoxime    B-Pyridine114692510
(    O
HI-6    O
)    O
are    O
used    O
to    O
restore    O
enzyme    O
functionality    O
.    O

Formation    O
of    O
supermicelles    O
from    O
various    O
block    O
copolymers    O
:    O
a    O
hydroxyl    O
-    O
functionalized    O
polymethylvinylsiloxane    O
(    O
HD    O
)    O
,    O
an    O
H    O
-    O
bonding    O
acceptor    O
block    O
2-vinylpyridine    B-Pyridine114692510
)    O
(    O
HA    O
)    O
,    O
a    O
non    O
-    O
interactive    O
block    O
poly(tert    O
-    O
butyl    O
acrylate    O
(    O
N    O
)    O
,    O
and    O
a    O
crosslinkable    O
block    O
poly(methylvinylsiloxane    O
)    O
(    O
X    O
)    O
.    O

Nonabine    B-Pyridine114692510
(    O
BRL-4664    B-Pyridine114692510
)    O
is    O
a    O
drug    O
which    O
is    O
a    O
cannabinoid    O
derivative    O
,    O
which    O
was    O
developed    O
for    O
the    O
prevention    O
of    O
nausea    O
and    O
vomiting    O
associated    O
with    O
cancer    O
chemotherapy    O
.    O

Cotinine    O
was    O
developed    O
as    O
an    O
antidepressant    O
as    O
a    O
fumaric    O
acid    O
salt    O
,    O
cotinine    O
fumarate    O
,    O
to    O
be    O
sold    O
under    O
the    O
brand    O
name    O
Scotine    B-Pyridine114692510
but    O
it    O
was    O
never    O
marketed    O
.    O

CYP2A6    O
is    O
the    O
primary    O
enzyme    O
responsible    O
for    O
the    O
oxidation    O
of    O
nicotine    O
and    O
cotinine    B-Pyridine114692510
.    O

cotinine    B-Pyridine114692510
(    O
metabolite    O
of    O
nicotine    O
)    O

Rogletimide    B-Pyridine114692510
,    O
also    O
known    O
as    O
pyridoglutethimide    B-Pyridine114692510
,    O
is    O
a    O
drug    O
related    O
in    O
chemical    O
structure    O
to    O
the    O
sedative    O
glutethimide    O
,    O
but    O
instead    O
having    O
pharmacological    O
activity    O
as    O
a    O
selective    O
aromatase    O
inhibitor    O
similar    O
to    O
the    O
related    O
drug    O
aminoglutethimide    O
,    O
but    O
with    O
no    O
significant    O
sedative    O
effect    O
.    O

Indalpine    O
(    O
Upstene    O
)    O
and    O
zimelidine    B-Pyridine114692510
(    O
Normud    O
,    O
Zelmid    O
)    O
were    O
also    O
formerly    O
used    O
as    O
antidepressants    O
,    O
but    O
were    O
withdrawn    O
from    O
the    O
market    O
.    O

:    O
N06AB02    O
Zimelidine    B-Pyridine114692510

In    O
1983    O
Astra    O
withdrew    O
its    O
neuropharmacological    O
drug    O
Zelmid    B-Pyridine114692510
,    O
which    O
had    O
only    O
introduced    O
the    O
year    O
before    O
,    O
because    O
of    O
concerns    O
over    O
side    O
effects    O
.    O

SB-242084    B-Pyridine114692510
is    O
a    O
psychoactive    O
drug    O
and    O
research    O
chemical    O
which    O
acts    O
as    O
a    O
selective    O
antagonist    O
for    O
the    O
5HT2C    O
receptor    O
.    O

NNK    B-Pyridine114692510

Nicotine-derived    B-Pyridine114692510
nitrosamine    I-Pyridine114692510
ketone    I-Pyridine114692510
(    O
NNK    B-Pyridine114692510
)    O
,    O
also    O
known    O
as    O
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone    B-Pyridine114692510
,    O
is    O
one    O
of    O
the    O
key    O
tobacco    O
-    O
specific    O
nitrosamines    O
which    O
play    O
an    O
important    O
role    O
in    O
carcinogenesis    O
.    O

selective    O
ETA    O
receptor    O
antagonists    O
(    O
sitaxentan    O
,    O
ambrisentan    O
,    O
atrasentan    O
,    O
BQ-123    O
,    O
zibotentan    B-Pyridine114692510
)    O
,    O
which    O
affect    O
endothelin    O
A    O
receptors    O
.    O

More    O
refractory    O
cases    O
may    O
require    O
the    O
use    O
of    O
oral    O
niacinamide    B-Pyridine114692510
and    O
tetracycline    O
,    O
corticosteroids    O
,    O
azathioprine    O
,    O
or    O
chlorambucil    O
.    O

Other    O
supplements    O
may    O
also    O
be    O
needed    O
,    O
including    O
:    O
cobalamin    O
,    O
ascorbic    O
acid    O
,    O
folic    O
acid    O
,    O
nicotinamide    B-Pyridine114692510
,    O
zinc    O
,    O
phosphorus    O
(    O
dicalcium    O
phosphate    O
)    O
and    O
in    O
some    O
cases    O
taurine    O
,    O
especially    O
suitable    O
when    O
there    O
cardiocirculatory    O
impairment    O
.    O

It    O
was    O
discovered    O
by    O
J.G.    O
Hauge    O
as    O
the    O
third    O
redox    O
cofactor    O
after    O
nicotinamide    B-Pyridine114692510
and    O
flavin    O
in    O
bacteria    O
(    O
although    O
he    O
hypothesised    O
that    O
it    O
was    O
naphthoquinone    O
)    O
.    O

Niacinamide    B-Pyridine114692510
,    O
the    O
active    O
form    O
of    O
vitamin    O
B3    O
,    O
acts    O
as    O
a    O
chemo-    O
and    O
radio    O
-    O
sensitizing    O
agent    O
by    O
enhancing    O
tumor    O
blood    O
flow    O
,    O
thereby    O
reducing    O
tumor    O
hypoxia    O
.    O

vitamins    O
(    O
folic    O
acid    O
,    O
nicotinamide    B-Pyridine114692510
,    O
riboflavin    O
,    O
B12    O
)    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
nicotinamide    B-Pyridine114692510
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
1-methylnicotinamide    O
.    O

It    O
is    O
also    O
a    O
metabolite    O
of    O
nicotinamide    B-Pyridine114692510
(    O
vitamin    O
B3    O
)    O
.    O

Niacinamide    B-Pyridine114692510

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
nicotinamide    B-Pyridine114692510
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
nicotinate    O
and    O
NH3    O
.    O

Azerizin    O
is    O
claimed    O
to    O
be    O
a    O
proprietary    O
blend    O
of    O
the    O
natural    O
ingredients    O
nicotinamide    B-Pyridine114692510
,    O
azelaic    O
acid    O
,    O
quercetin    O
and    O
curcumin    O
that    O
purportedly    O
combine    O
the    O
anti    O
-    O
inflammatory    O
and    O
antimicrobial    O
properties    O
,    O
along    O
with    O
inhibiting    O
effects    O
on    O
sebum    O
production    O
.    O

Like    O
all    O
"    O
Bordetella    O
"    O
species    O
,    O
"    O
B.    O
trematum    O
"    O
is    O
a    O
chemoorganotroph    O
and    O
requires    O
nicotinamide    B-Pyridine114692510
,    O
organic    O
sulfur    O
such    O
as    O
cysteine    O
,    O
and    O
organic    O
nitrogen    O
such    O
as    O
amino    O
acids    O
for    O
growth    O
by    O
respiratory    O
metabolism    O
.    O

It    O
is    O
an    O
isomer    O
of    O
nicotinamide    B-Pyridine114692510
,    O
which    O
has    O
the    O
carboxamide    O
group    O
in    O
the    O
3-position    O
.    O

Nicotinamide    B-Pyridine114692510

However    O
,    O
they    O
require    O
compromises    O
in    O
borderline    O
cases    O
;    O
for    O
example    O
,    O
nicotine    O
contains    O
a    O
pyridine    O
fragment    O
from    O
nicotinamide    B-Pyridine114692510
and    O
pyrrolidine    O
part    O
from    O
ornithine    O
and    O
therefore    O
can    O
be    O
assigned    O
to    O
both    O
classes    O
.    O

Desloratadine    B-Pyridine114692510

Loratadine    B-Pyridine114692510
,    O
another    O
non    O
-    O
sedating    O
antihistamine    O
,    O
is    O
the    O
prodrug    O
of    O
desloratadine    B-Pyridine114692510
,    O
which    O
is    O
largely    O
responsible    O
for    O
the    O
antihistaminergic    O
effects    O
of    O
the    O
parent    O
compound    O
.    O

desloratadine    B-Pyridine114692510

It    O
contains    O
two    O
active    O
ingredients    O
:    O
carbinoxamine    B-Pyridine114692510
and    O
pseudoephedrine    O
.    O

A    O
class    O
of    O
antihistamines    O
is    O
identified    O
as    O
ethanolamines    O
,    O
which    O
includes    O
carbinoxamine    B-Pyridine114692510
,    O
clemastine    O
,    O
dimenhydrinate    O
,    O
diphenhydramine    O
,    O
and    O
doxylamine    O
.    O

Phenopicolinic    B-Pyridine114692510
acid    I-Pyridine114692510
is    O
a    O
dopamine    O
beta    O
hydroxylase    O
inhibitor    O
.    O

Some    O
of    O
these    O
techniques    O
,    O
such    O
as    O
ninhydrin    O
,    O
diazafluorenone    B-Pyridine114692510
and    O
vacuum    O
metal    O
deposition    O
,    O
show    O
great    O
sensitivity    O
and    O
are    O
used    O
operationally    O
.    O

doxpicomine    B-Pyridine114692510
(    O
INN    O
)    O

Tebanicline    B-Pyridine114692510
(    O
Ebanicline    B-Pyridine114692510
,    O
ABT-594    B-Pyridine114692510
)    O
is    O
a    O
potent    O
synthetic    O
nicotinic    O
(    O
non    O
-    O
opioid    O
)    O
analgesic    O
drug    O
developed    O
by    O
Abbott    O
.    O

Tris(2-pyridylmethyl)amine    B-Pyridine114692510
(    O
abbreviated    O
TPMA    O
or    O
TPA    O
)    O
is    O
an    O
organic    O
compound    O
with    O
the    O
formula    O
(    O
C5H4NCH2)3N.    O
It    O
is    O
a    O
tertiary    O
amine    O
with    O
three    O
picolyl    B-Pyridine114692510
substituents    O
.    O

4-Aminopyridine    B-Pyridine114692510

Among    O
these    O
products    O
,    O
five    O
are    O
primary    O
to    O
the    O
company    O
:    O
risperidone    O
long    O
-    O
acting    O
Injection    O
(    O
generic    O
for    O
"    O
Risperdal    O
Consta    O
"    O
)    O
for    O
schizophrenia    O
and    O
bipolar    O
1    O
disorder    O
,    O
paliperidone    O
palmitate    O
(    O
generic    O
for    O
"    O
Invega    O
Sustenna    O
"    O
in    O
the    O
U.S.    O
,    O
"    O
Xeplion    O
"    O
in    O
Europe    O
)    O
for    O
schizophrenia    O
,    O
4-aminopyridine    B-Pyridine114692510
(    O
generic    O
for    O
"    O
Ampyra    O
"    O
in    O
the    O
U.S.    O
,    O
"    O
Fampyra    O
"    O
in    O
Europe    O
)    O
to    O
improve    O
walking    O
in    O
patients    O
with    O
multiple    O
sclerosis    O
,    O
naltrexone    O
for    O
extended    O
-    O
release    O
injectable    O
suspension    O
(    O
generic    O
for    O
"    O
Vivitrol    O
"    O
)    O
for    O
alcohol    O
and    O
opioid    O
dependence    O
,    O
and    O
exenatide    O
extended    O
-    O
release    O
for    O
injectable    O
suspension    O
(    O
generic    O
for    O
"    O
Bydureon    O
"    O
)    O
for    O
the    O
treatment    O
of    O
type    O
2    O
diabetes    O
.    O

4-Aminopyridine    B-Pyridine114692510

4-Aminopyridine    B-Pyridine114692510

Ruthenium    O
polypyridine    B-Pyridine114692510
complex    I-Pyridine114692510
,    O
in    O
particular    O
tris(bipyridine)ruthenium(II    O
)    O
and    O
its    O
derivatives    O
,    O
have    O
been    O
extensively    O
used    O
in    O
hydrogen    O
photoproduction    O
due    O
to    O
their    O
efficient    O
visible    O
light    O
absorption    O
and    O
long    O
-    O
lived    O
consequent    O
metal    O
-    O
to    O
-    O
ligand    O
charge    O
transfer    O
excited    O
state    O
,    O
which    O
makes    O
the    O
complexes    O
strong    O
reducing    O
agents    O
.    O

Bradanicline    B-Pyridine114692510
(    O
INN    O
,    O
code    O
name    O
TC-5619    B-Pyridine114692510
)    O
is    O
a    O
drug    O
which    O
was    O
being    O
developed    O
by    O
Targacept    O
that    O
acts    O
as    O
a    O
partial    O
agonist    O
at    O
the    O
α7    O
subtype    O
of    O
the    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

The    O
C1    O
,    O
C2    O
and    O
C4    O
functional    O
groups    O
were    O
put    O
in    O
place    O
next    O
and    O
starting    O
from    O
oxetane    O
5.1    O
(    O
"    O
scheme    O
5    O
"    O
)    O
the    O
MOM    O
protecting    O
group    O
is    O
removed    O
in    O
5.2    O
(    O
PPTS    B-Pyridine114692510
)    O
and    O
replaced    O
by    O
a    O
TES    O
group    O
TESCl    O
)    O
in    O
5.3    O
.    O

lafutidine    B-Pyridine114692510
(    O
INN    O
)    O

Piberaline    B-Pyridine114692510
–    O
Antidepressant    O

Cyantraniliprole    B-Pyridine114692510
is    O
an    O
insecticide    O
of    O
the    O
ryanoid    O
class    O
.    O

GSK-189,254    B-Pyridine114692510
is    O
a    O
potent    O
and    O
selective    O
H3    O
histamine    O
receptor    O
inverse    O
agonist    O
developed    O
by    O
GlaxoSmithKline    O
.    O

enzastaurin    B-Pyridine114692510
(    O
USAN    O
)    O

3-Methylpyridine    B-Pyridine114692510

mocetinostat    B-Pyridine114692510
(    O
USAN    O
,    O
INN    O
)    O

The    O
structures    O
of    O
these    O
cross    O
-    O
linked    O
amino    O
acids    O
had    O
3,4,5-    O
and    O
2,3,5-trisubstituted    O
pyridine    O
skeletons    O
,    O
specifically    O
pyridinated    O
desmosine    B-Pyridine114692510
(    O
DESP    O
)    O
and    O
pyridinated    O
isodesmosine    O
(    O
IDP    O
)    O
.    O

Protection    O
:    O
methanol    O
,    O
collidine    B-Pyridine114692510
p-toluenesulfonate    I-Pyridine114692510

The    O
Mk    O
I    O
Nerve    O
Agent    O
Antidote    O
Kit    O
(    O
NAAK    O
)    O
consists    O
of    O
a    O
pair    O
of    O
autoinjectors    O
containing    O
atropine    O
sulfate    O
and    O
pralidoxime    B-Pyridine114692510
chloride    I-Pyridine114692510
for    O
first    O
aid    O
against    O
nerve    O
agents    O
,    O
and    O
are    O
due    O
to    O
be    O
replaced    O
by    O
the    O
single    O
ATNAA    O
.    O

Pralidoxime    B-Pyridine114692510
can    O
be    O
used    O
to    O
act    O
against    O
organophosphate    O
poisoning    O
,    O
this    O
must    O
be    O
given    O
as    O
fast    O
as    O
possible    O
after    O
the    O
ethion    O
poisoning    O
for    O
its    O
efficacy    O
is    O
inhibited    O
by    O
the    O
chemical    O
change    O
of    O
ethion    O
-    O
enzyme    O
in    O
the    O
body    O
that    O
occurs    O
over    O
time    O
.    O

If    O
poisoning    O
occurs    O
,    O
a    O
physician    O
may    O
administer    O
atropine    O
sulfate    O
,    O
or    O
pralidoxime    B-Pyridine114692510
in    O
case    O
of    O
severe    O
poisoning    O
.    O

Oximes    O
such    O
as    O
obidoxime    O
,    O
pralidoxime    B-Pyridine114692510
and    O
asoxime    B-Pyridine114692510
(    O
HI-6    O
)    O
are    O
used    O
to    O
restore    O
enzyme    O
functionality    O
.    O

The    O
Michael    O
J.    O
Fox    O
Foundation    O
subsequently    O
announced    O
that    O
it    O
was    O
supporting    O
proof    O
-    O
of    O
-    O
principle    O
studies    O
on    O
befiradol    B-Pyridine114692510
in    O
models    O
of    O
Parkinson    O
's    O
disease    O
and    O
showcased    O
Neurolixis    O
in    O
its    O
Partnering    O
Program    O
.    O

Befiradol    B-Pyridine114692510

:*    O
pantoprazole    B-Pyridine114692510

The    O
admission    O
resident    O
doctor    O
prescribed    O
the    O
patient    O
with    O
her    O
usual    O
medications    O
(    O
including    O
aspirin    O
,    O
calcium    O
carbonate    O
,    O
Lasix    O
and    O
Pantoloc    B-Pyridine114692510
)    O
.    O

Proton    O
pump    O
inhibitors    O
(    O
PPIs    O
)    O
:    O
The    O
PPIs    O
include    O
omeprazole    O
(    O
Prilosec    O
,    O
Losec    O
)    O
,    O
lansoprazole    O
(    O
Prevacid    O
)    O
,    O
rabeprazole    B-Pyridine114692510
(    O
Aciphex    O
)    O
,    O
pantoprazole    B-Pyridine114692510
(    O
Protonix    O
,    O
Pantoloc    O
)    O
,    O
and    O
esomeprazole    B-Pyridine114692510
(    O
Nexium    O
)    O
.    O

Pantoprazole    B-Pyridine114692510
(    O
brand    O
names    O
:    O
Protonix    O
,    O
Somac    O
,    O
Pantoloc    O
,    O
Pantozol    O
,    O
Zurcal    O
,    O
Zentro    O
,    O
Pan    O
,    O
Nolpaza    O
,    O
Controloc    O
,    O
Sunpras    O
)    O

Quinolinic    B-Pyridine114692510
acid    I-Pyridine114692510
,    O
a    O
dicarboxylic    O
acid    O

A    O
hypothesized    O
mechanism    O
for    O
inflammation    O
in    O
CFS    O
proposes    O
that    O
inflammation    O
inhibits    O
serotonin    O
synthesis    O
through    O
the    O
Trycat    B-Pyridine114692510
pathway    O
.    O

Dysfunctional    O
states    O
of    O
distinct    O
steps    O
of    O
the    O
kynurenine    O
pathway    O
(    O
e.g.    O
kynurenine    O
,    O
kynurenic    O
acid    O
,    O
quinolinic    B-Pyridine114692510
acid    I-Pyridine114692510
,    O
anthranilic    O
acid    O
,    O
3    O
-Hydroxykynurenine    O
)    O
have    O
been    O
described    O
for    O
a    O
number    O
of    O
disorders    O
,    O
e.g.    O
:    O

One    O
of    O
its    O
products    O
,    O
delafloxacin    B-Pyridine114692510
,    O
a    O
fluoroquinolone    O
antibiotic    O
acquired    O
from    O
Wakunaga    O
Pharmaceutical    O
in    O
2006    O
,    O
was    O
approved    O
by    O
the    O
FDA    O
in    O
2017    O
.    O

tesetaxel    B-Pyridine114692510
(    O
INN    O
)    O

One    O
such    O
pharmaceutical    O
application    O
is    O
in    O
the    O
synthesis    O
of    O
SIB-1508Y    O
,    O
which    O
is    O
more    O
commonly    O
known    O
as    O
Altinicline    B-Pyridine114692510
.    O

Proton    O
pump    O
inhibitors    O
(    O
PPIs    O
)    O
:    O
The    O
PPIs    O
include    O
omeprazole    O
(    O
Prilosec    O
,    O
Losec    O
)    O
,    O
lansoprazole    O
(    O
Prevacid    O
)    O
,    O
rabeprazole    B-Pyridine114692510
(    O
Aciphex    O
)    O
,    O
pantoprazole    B-Pyridine114692510
(    O
Protonix    O
,    O
Pantoloc    O
)    O
,    O
and    O
esomeprazole    B-Pyridine114692510
(    O
Nexium    O
)    O
.    O

Rabeprazole    B-Pyridine114692510
(    O
brand    O
names    O
:    O
Zechin    O
,    O
Rabecid    O
,    O
Nzole    O
-    O
D    O
,    O
AcipHex    O
,    O
Pariet    O
,    O
Rabeloc    O
,    O
Zulbex    O
,    O
Ontime    O
,    O
Noflux    O
)    O

Terbogrel    B-Pyridine114692510
(    O
INN    O
)    O
blocks    O
thromboxanes    O
and    O
is    O
expected    O
to    O
be    O
useful    O
in    O
treating    O
the    O
vasoconstricting    O
and    O
platelet    O
-    O
aggregating    O
action    O
of    O
this    O
compound    O
.    O

Pioglitazone    B-Pyridine114692510
(    O
brand    O
name    O
Actos    B-Pyridine114692510
)    O
is    O
a    O
prescription    O
drug    O
of    O
the    O
thiazolidinedione    O
(    O
TZD    O
)    O
class    O
with    O
hypoglycemic    O
(    O
antihyperglycemic    O
,    O
antidiabetic    O
)    O
action    O
to    O
treat    O
diabetes    O
.    O

During    O
Caro´s    O
tenure    O
the    O
endocrine    O
portfolio    O
of    O
Lilly    O
products    O
grew    O
from    O
insulin    O
and    O
Humatrope    O
to    O
include    O
Byetta    O
,    O
Actos    B-Pyridine114692510
,    O
Evista    O
and    O
Forteo    O
.    O

Adams    O
has    O
hypothesized    O
that    O
heavy    O
metals    O
,    O
particularly    O
cadmium    O
and    O
mercury    O
,    O
may    O
play    O
a    O
role    O
in    O
the    O
pathogenesis    O
of    O
autism    O
,    O
and    O
has    O
advocated    O
treatment    O
with    O
chelation    O
therapy    O
and    O
pioglitazone    B-Pyridine114692510
,    O
though    O
evidence    O
supporting    O
both    O
the    O
association    O
and    O
the    O
treatment    O
is    O
anecdotal    O
at    O
best    O
.    O

In    O
1998    O
Takeda    O
established    O
its    O
own    O
US    O
R&D    O
and    O
sales    O
force    O
,    O
for    O
the    O
diabetes    O
drug    O
pioglitazone    B-Pyridine114692510
(    O
Actos    O
)    O
.    O

Multi    O
-    O
drug    O
therapy    O
using    O
insulin    O
sensitizers    O
,    O
such    O
as    O
metformin    O
and    O
pioglitazone    B-Pyridine114692510
,    O
has    O
been    O
linked    O
to    O
improving    O
residual    O
insulin    O
action    O
.    O

995    O
patients    O
were    O
randomized    O
to    O
receive    O
either    O
insulin    O
degludec    O
(    O
n=755    O
)    O
or    O
insulin    O
glargine    O
(    O
n=251    O
)    O
,    O
in    O
addition    O
to    O
either    O
mealtime    O
insulin    O
aspart    O
,    O
metformin    O
,    O
and/or    O
pioglitazone    B-Pyridine114692510
.    O

Examples    O
include    O
the    O
"    O
Escherichia    O
coli    O
"    O
TolC    O
outer    O
membrane    O
protein    O
,    O
which    O
is    O
required    O
for    O
proper    O
expression    O
of    O
outer    O
membrane    O
protein    O
genes    O
;    O
the    O
Rhizobium    O
nodulation    O
protein    O
;    O
and    O
the    O
Pseudomonas    O
FusA    O
protein    O
,    O
which    O
is    O
involved    O
in    O
resistance    O
to    O
fusaric    B-Pyridine114692510
acid    I-Pyridine114692510
.    O

Rivanicline    B-Pyridine114692510
(    O
TC-2403    B-Pyridine114692510
,    O
RJR-2403    B-Pyridine114692510
,    O
(E)-metanicotine    B-Pyridine114692510
)    O
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
partial    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

It    O
does    O
not    O
methylate    O
benzene    O
or    O
the    O
bulky    O
2,6-di-"tert"-butylpyridine    B-Pyridine114692510
.    O

Crizotinib    B-Pyridine114692510
was    O
the    O
first    O
of    O
these    O
drugs    O
to    O
enter    O
clinical    O
trials    O
and    O
is    O
the    O
sole    O
available    O
ALK    O
inhibitor    O
,    O
approved    O
by    O
the    O
FDA    O
on    O
August    O
26    O
,    O
2011    O
.    O

It    O
has    O
been    O
suggested    O
that    O
mesoblastic    O
nephroma    O
patients    O
with    O
lymph    O
node    O
involvement    O
or    O
recurrent    O
disease    O
might    O
benefit    O
by    O
adding    O
the    O
ALK    O
inhibitor    O
,    O
crizotinib    B-Pyridine114692510
,    O
or    O
a    O
tyrosine    O
kinase    O
inhibitor    O
,    O
either    O
larotrectinib    O
or    O
entrectinib    O
,    O
to    O
surgical    O
,    O
radiation    O
,    O
and/or    O
chemotherapy    O
treatment    O
regimens    O
.    O

He    O
is    O
also    O
the    O
first    O
researcher    O
who    O
(    O
in    O
June    O
2010    O
)    O
successfully    O
treated    O
a    O
patient    O
affected    O
by    O
ALK+    O
lymphoma    O
with    O
an    O
ALK    O
inhibitor    O
(    O
crizotinib    B-Pyridine114692510
)    O
.    O

Lasmiditan    B-Pyridine114692510

Clopidol    B-Pyridine114692510
is    O
an    O
organic    O
compound    O
that    O
is    O
used    O
as    O
in    O
veterinary    O
medicine    O
as    O
a    O
coccidiostat    O
.    O

Another    O
route    O
is    O
the    O
partial    O
reduction    O
of    O
myosmine    B-Pyridine114692510
,    O
which    O
can    O
be    O
accomplished    O
by    O
standard    O
catalytic    O
hydrogenation    O
conditions    O
using    O
palladium    O
as    O
a    O
catalyst    O
.    O
or    O
with    O
sodium    O
borohydride    O

The    O
of    O
annonacin    O
to    O
dopaminergic    O
neurons    O
is    O
0.018    O
uM    O
,    O
which    O
when    O
compared    O
to    O
other    O
known    O
neurotoxins    O
is    O
100-fold    O
more    O
toxic    O
than    O
1-methyl-4-phenylpyridinium    B-Pyridine114692510
(    O
MPP    O
)    O
,    O
700    O
fold    O
more    O
than    O
coreximine    O
,    O
and    O
twice    O
rotenone    O
.    O

In    O
flies    O
,    O
activation    O
of    O
the    O
D2    O
autoreceptor    O
protected    O
dopamine    O
neurons    O
from    O
cell    O
death    O
induced    O
by    O
MPP+    B-Pyridine114692510
,    O
a    O
toxin    O
mimicking    O
Parkinson    O
's    O
disease    O
pathology    O
.    O

This    O
fruit    O
is    O
one    O
of    O
the    O
few    O
to    O
have    O
indicaxanthin    B-Pyridine114692510
,    O
a    O
betalain    O
,    O
a    O
type    O
of    O
plant    O
pigment    O
antioxidant    O
.    O

Eight    O
betaxanthins    O
(    O
indicaxanthin    B-Pyridine114692510
,    O
vulgaxanthin    O
-    O
I    O
,    O
miraxanthin    O
-    O
I    O
,    O
-II    O
,    O
-III    O
,    O
-IV    O
,    O
-V    O
and    O
-VI    O
)    O
can    O
be    O
isolated    O
from    O
"    O
M.    O
jalapa    O
"    O
flowers    O
.    O

MPEP    B-Pyridine114692510

MPEP    B-Pyridine114692510

In    O
2008    O
,    O
the    O
park    O
began    O
to    O
use    O
the    O
herbicides    O
glyphosate    O
and    O
aminopyralid    B-Pyridine114692510
to    O
augment    O
manual    O
methods    O
to    O
manage    O
the    O
most    O
threatening    O
plants    O
.    O

Antihistamines    O
such    O
as    O
betahistine    B-Pyridine114692510
,    O
dimenhydrinate    O
,    O
or    O
meclizine    O
,    O
which    O
may    O
have    O
antiemetic    O
properties    O

Betahistine    B-Pyridine114692510
(    O
brand    O
names    O
Veserc    B-Pyridine114692510
,    O
Serc    B-Pyridine114692510
,    O
Hiserk    B-Pyridine114692510
,    O
Betaserc    B-Pyridine114692510
,    O
Vergo    B-Pyridine114692510
)    O
is    O
an    O
anti    O
-    O
vertigo    O
drug    O
.    O

Dipicolinic    B-Pyridine114692510
acid    I-Pyridine114692510
,    O
a    O
dicarboxylic    O
acid    O

Dipicolinic    B-Pyridine114692510
acid    I-Pyridine114692510
,    O
a    O
chemical    O
compound    O
found    O
in    O
bacterial    O
spores    O

Protionamide    B-Pyridine114692510
(    O
or    O
prothionamide    B-Pyridine114692510
)    O
is    O
a    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
tuberculosis    O
.    O

Mefway    B-Pyridine114692510

pirenzepine    B-Pyridine114692510

Pirenzepine    B-Pyridine114692510
(    O
M1    O
selective    O
antagonist    O
)    O

:    O
C04AE02    O
Nicergoline    B-Pyridine114692510

Commercially    O
available    O
organobromine    O
pharmaceuticals    O
include    O
the    O
vasodilator    O
nicergoline    B-Pyridine114692510
,    O
the    O
sedative    O
brotizolam    O
,    O
the    O
anticancer    O
agent    O
pipobroman    O
,    O
and    O
the    O
antiseptic    O
merbromin    O
.    O

However    O
,    O
sequential    O
small    O
molecule    O
treatment    O
of    O
the    O
muscle    O
fiber    O
with    O
myoseverin    O
,    O
reversine    O
(    O
the    O
aurora    O
B    O
kinase    O
inhibitor    O
)    O
and    O
some    O
other    O
chemicals    O
:    O
BIO    O
(    O
glycogen    O
synthase-3    O
kinase    O
inhibitor    O
)    O
,    O
lysophosphatidic    O
acid    O
(    O
pleiotropic    O
activator    O
of    O
G    O
-    O
protein    O
-    O
coupled    O
receptors    O
)    O
,    O
SB203580    B-Pyridine114692510
(    O
p38    O
MAP    O
kinase    O
inhibitor    O
)    O
,    O
or    O
SQ22536    O
(    O
adenylyl    O
cyclase    O
inhibitor    O
)    O
causes    O
the    O
formation    O
of    O
new    O
muscle    O
cell    O
types    O
as    O
well    O
as    O
other    O
cell    O
types    O
such    O
as    O
precursors    O
to    O
fat    O
,    O
bone    O
and    O
nervous    O
system    O
cells    O
.    O

Sarizotan    B-Pyridine114692510

WAY-317,538    B-Pyridine114692510

There    O
are    O
several    O
classes    O
of    O
cationic    O
initiators    O
including    O
:    O
Onium    O
salts    O
,    O
organometallic    O
compounds    O
and    O
pyridinium    B-Pyridine114692510
salts    O
.    O

Generally    O
pyridinium    B-Pyridine114692510
photoinitiators    O
are    O
N    O
-    O
substituted    O
pyridine    O
derivatives    O
,    O
with    O
a    O
positive    O
charge    O
placed    O
on    O
the    O
nitrogen    O
.    O

Nucleophilic    O
attack    O
by    O
alcohol    O
4    O
and    O
deprotonation    O
by    O
pyridine    O
(    O
5    O
)    O
gives    O
intermediate    O
6    O
,    O
an    O
alkoxysulfonium    O
ion    O
associated    O
with    O
the    O
anionic    O
pyridinium    B-Pyridine114692510
sulfate    O
complex    O
.    O

pyridinium    B-Pyridine114692510
,    O
(    O
protonated    O
pyridine    O
)    O

But    O
unlike    O
the    O
MTO    O
-    O
catalyzed    O
variant    O
,    O
the    O
urea    O
-    O
catalyzed    O
variant    O
does    O
not    O
produce    O
potentially    O
toxic    O
heavy    O
metal    O
waste    O
;    O
it    O
has    O
also    O
been    O
applied    O
to    O
the    O
synthesis    O
of    O
amine    O
oxides    O
such    O
as    O
pyridine-"N"-oxide    B-Pyridine114692510
.    O

Later    O
in    O
his    O
career    O
,    O
he    O
reported    O
the    O
synthesis    O
of    O
the    O
pyridine-N-oxide    B-Pyridine114692510
.    O

Cefpimizole    B-Pyridine114692510
(    O
INN    O
)    O
is    O
a    O
third    O
-    O
generation    O
cephalosporin    O
antibiotic    O
.    O

In    O
addition    O
,    O
coadministration    O
of    O
sofosbuvir    O
with    O
anticonvulsants    O
(    O
carbamazepine    O
,    O
phenytoin    O
,    O
phenobarbital    O
,    O
oxcarbazepine    O
)    O
,    O
antimycobacterials    O
(    O
rifampin    O
,    O
rifabutin    O
,    O
rifapentine    O
)    O
,    O
and    O
the    O
HIV    O
protease    O
inhibitor    O
tipranavir    B-Pyridine114692510
and    O
ritonavir    O
is    O
expected    O
to    O
decrease    O
sofosbuvir    O
concentration    O
.    O

Protease    O
inhibitors    O
such    O
as    O
tipranavir    B-Pyridine114692510
or    O
ritonovir    O
may    O
decrease    O
the    O
serum    O
concentration    O
of    O
abacavir    O
through    O
induction    O
of    O
glucuronidation    O
.    O

PSN-375,963    B-Pyridine114692510

They    O
include    O
direct    O
glucocorticoid    O
receptor    O
antagonists    O
such    O
as    O
mifepristone    O
and    O
synthesis    O
inhibitors    O
such    O
as    O
metyrapone    B-Pyridine114692510
,    O
ketoconazole    O
,    O
and    O
aminoglutethimide    O
.    O

Metyrapone    B-Pyridine114692510
blocks    O
GC    O
secretion    O

metyrapone    B-Pyridine114692510
(    O
used    O
to    O
diagnose    O
adrenal    O
insufficiency    O
)    O

Taranabant    B-Pyridine114692510

EMD-386,088    B-Pyridine114692510

Bupicomide    B-Pyridine114692510

Lurtotecan    O
is    O
a    O
semi    O
-    O
synthetic    O
analog    O
of    O
camptothecin    B-Pyridine114692510
with    O
antineoplastic    O
activity    O
.    O

Exatecan    O
is    O
a    O
drug    O
which    O
is    O
an    O
analogue    O
of    O
camptothecin    B-Pyridine114692510
with    O
antineoplastic    O
activity    O
.    O

Many    O
indole    O
alkaloids    O
formed    O
from    O
strictosidine    O
synthase    O
-    O
catalyzed    O
condensation    O
are    O
important    O
precursors    O
to    O
medicinally    O
important    O
compounds    O
such    O
as    O
quinine    O
,    O
the    O
antineoplastic    O
drug    O
camptothecin    B-Pyridine114692510
,    O
and    O
anticancer    O
drugs    O
vincristine    O
and    O
vinblastine    O
.    O
Because    O
of    O
this    O
,    O
strictosidine    O
synthase    O
is    O
widely    O
known    O
as    O
the    O
enzyme    O
of    O
choice    O
for    O
investigations    O
towards    O
chemoenzymatic    O
alkaloid    O
synthesis    O
.    O

He    O
is    O
co    O
-    O
discoverer    O
of    O
Taxol    O
and    O
camptothecin    B-Pyridine114692510
,    O
two    O
anti    O
-    O
cancer    O
drugs    O
considered    O
standard    O
in    O
the    O
treatment    O
to    O
fight    O
ovarian    O
,    O
breast    O
,    O
lung    O
and    O
colon    O
cancers    O
.    O

One    O
study    O
which    O
did    O
address    O
this    O
topic    O
used    O
flow    O
cytometry    O
or    O
elutriation    O
of    O
synchronized    O
cells    O
treated    O
with    O
actinomycin    O
D1    O
,    O
camptothecin    B-Pyridine114692510
,    O
or    O
aphidicolin    O
,    O
each    O
of    O
which    O
had    O
been    O
documented    O
to    O
exert    O
its    O
effects    O
in    O
a    O
particular    O
phase    O
of    O
the    O
cell    O
cycle    O
.    O

Nemertelline    B-Pyridine114692510

Diphenyl-2-pyridylphosphine    B-Pyridine114692510
(    O
a    O
phosphorus    O
atom    O
replaces    O
the    O
Methanetriyl    O
group    O
)    O
.    O

CP-94253    B-Pyridine114692510
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
potent    O
and    O
selective    O
serotonin    O
5-HT1B    O
receptor    O
agonist    O
,    O
with    O
approximately    O
25x    O
and    O
40x    O
selectivity    O
over    O
the    O
closely    O
related    O
5-HT1D    O
and    O
5-HT1A    O
receptors    O
.    O

dual    O
antagonists    O
(    O
bosentan    O
,    O
macitentan    O
,    O
tezosentan    B-Pyridine114692510
)    O
,    O
which    O
affect    O
both    O
endothelin    O
A    O
and    O
B    O
receptors    O
.    O

Leaving    O
the    O
town    O
on    O
5    O
April    O
,    O
the    O
party    O
travelled    O
on    O
to    O
Khengu    O
over    O
the    O
Bahman    O
Dopté    O
pass    O
;    O
at    O
Khengu    O
Lopsang    O
Tsering    O
fell    O
off    O
his    O
pony    O
and    O
broke    O
his    O
collarbone    O
;    O
the    O
anaesthetic    O
administered    O
by    O
Greene    O
stopped    O
his    O
heart    O
,    O
and    O
only    O
vigorous    O
resuscitation    O
,    O
aided    O
by    O
coramine    B-Pyridine114692510
,    O
saved    O
his    O
life    O
.    O

In    O
1972    O
he    O
finished    O
third    O
in    O
the    O
100    O
km    O
team    O
time    O
trial    O
at    O
the    O
Munich    O
Olympics    O
,    O
but    O
tested    O
positive    O
for    O
Coramine    B-Pyridine114692510
,    O
a    O
drug    O
allowed    O
by    O
the    O
Union    O
Cycliste    O
Internationale    O
but    O
not    O
the    O
IOC    O
.    O

Official    O
sources    O
have    O
stated    O
the    O
banned    O
substance    O
taken    O
was    O
nikethamide    B-Pyridine114692510
,    O
a    O
stimulant    O
,    O
and    O
that    O
it    O
had    O
been    O
taken    O
three    O
hours    O
prior    O
to    O
the    O
game    O
in    O
which    O
he    O
passed    O
.    O

Like    O
lapatinib    O
and    O
neratinib    B-Pyridine114692510
,    O
afatinib    O
is    O
a    O
protein    O
kinase    O
inhibitor    O
that    O
also    O
irreversibly    O
inhibits    O
human    O
epidermal    O
growth    O
factor    O
receptor    O
2    O
(    O
Her2    O
)    O
and    O
epidermal    O
growth    O
factor    O
receptor    O
(    O
EGFR    O
)    O
kinases    O
.    O

Guareschi–Thorpe    B-Pyridine114692510
condensation    I-Pyridine114692510

In    O
1894    O
he    O
discovered    O
a    O
reaction    O
to    O
synthesise    O
2-Pyridone    B-Pyridine114692510
,    O
today    O
known    O
as    O
the    O
Guareschi-Thorpe    B-Pyridine114692510
condensation    I-Pyridine114692510
.    O

Flupirtine    B-Pyridine114692510
is    O
a    O
centrally    O
acting    O
K+    O
channel    O
opener    O
with    O
weak    O
NMDA    O
antagonist    O
properties    O
.    O

Dianicline    B-Pyridine114692510
(    O
SSR-591,813    B-Pyridine114692510
)    O
is    O
a    O
drug    O
developed    O
by    O
Sanofi    O
-    O
Aventis    O
which    O
acts    O
as    O
a    O
partial    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

The    O
project    O
was    O
centered    O
on    O
,    O
but    O
not    O
restricted    O
to    O
,    O
the    O
use    O
of    O
anabasine    B-Pyridine114692510
(    O
an    O
alkaloid    O
)    O
,    O
scopolamine    O
and    O
mescaline    O
.    O

Prior    O
to    O
the    O
development    O
of    O
a    O
wide    O
range    O
of    O
relatively    O
low    O
-    O
toxic    O
synthetic    O
pesticides    O
,    O
some    O
alkaloids    O
,    O
such    O
as    O
salts    O
of    O
nicotine    O
and    O
anabasine    B-Pyridine114692510
,    O
were    O
used    O
as    O
insecticides    O
.    O

HZ-2    B-Pyridine114692510
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
highly    O
selective    O
κ-opioid    O
agonist    O
.    O

ABT-724    B-Pyridine114692510

Pyridinylpiperazine    B-Pyridine114692510

For    O
example    O
,    O
2-methylpyridine    B-Pyridine114692510
,    O
4-methylpyridine    B-Pyridine114692510
and    O
2-ethyl-5-methylpyridine    O
exhibit    O
widespread    O
use    O
in    O
syntheses    O
of    O
latexes    O
,    O
ion    O
-    O
exchange    O
matrixes    O
,    O
and    O
photography    O
materials    O
.    O

Claritin    B-Pyridine114692510
,    O
An    O
anti    O
-    O
histamine    O
marketed    O
in    O
alliance    O
with    O
Schering    O
-    O
Plough    O
.    O

Loratadine    B-Pyridine114692510

Unlike    O
loratadine    B-Pyridine114692510
or    O
fexofenadine    O
,    O
clemastine    O
is    O
a    O
sedating    O
antihistamine    O
;    O
however    O
,    O
it    O
exhibits    O
fewer    O
other    O
side    O
effects    O
than    O
most    O
of    O
the    O
widely    O
used    O
antihistamines    O
.    O

Their    O
clients    O
included    O
major    O
companies    O
such    O
as    O
Schering    O
-    O
Plough    O
(    O
for    O
a    O
website    O
about    O
the    O
Clarityn    B-Pyridine114692510
antihistamine    O
)    O
.    O

Schering    O
-    O
Plough    O
and    O
Merck    O
sought    O
permission    O
to    O
market    O
a    O
combined    O
tablet    O
with    O
loratadine    B-Pyridine114692510
(    O
Claritin    O
)    O
and    O
montelukast    O
(    O
Singulair    O
)    O
,    O
as    O
many    O
patients    O
combine    O
the    O
two    O
themselves    O
.    O

In    O
2012    O
,    O
Corwin    O
starred    O
in    O
a    O
Claritin    B-Pyridine114692510
commercial    O
as    O
himself    O
.    O

The    O
organization    O
also    O
contacted    O
several    O
of    O
their    O
advertisers    O
over    O
the    O
issue    O
,    O
including    O
Lowe    O
's    O
,    O
Campbell    O
's    O
Soup    O
,    O
Claritin    B-Pyridine114692510
,    O
Geico    O
,    O
McDonald    O
's    O
and    O
Taco    O
Bell    O
.    O

The    O
non    O
-    O
sedating    O
antihistamine    O
loratidine    B-Pyridine114692510
had    O
no    O
effect    O
on    O
any    O
of    O
the    O
measures    O
studied    O
.    O

2,6-Lutidine    B-Pyridine114692510
is    O
a    O
natural    O
heterocyclic    O
aromatic    O
organic    O
compound    O
with    O
the    O
formula    O
(    O
CH3)2C5H3N.    O

A    O
Mukaiyama    O
aldol    O
addition    O
(    O
magnesium    O
bromide    O
/    O
toluene    O
)    O
took    O
place    O
between    O
aldehyde    O
7    O
and    O
ketene    O
silyl    O
acetal    O
8    O
with    O
71%    O
stereoselectivity    O
to    O
alcohol    O
9    O
which    O
was    O
protected    O
as    O
the    O
TBS    O
ether    O
10    O
(    O
TBSOTf    O
,    O
2,6-lutidine    B-Pyridine114692510
)    O
.    O

After    O
deprotection    O
(    O
pinacol    O
)    O
to    O
diol    O
2.6    O
,    O
DIBAL    O
reduction    O
to    O
triol    O
2.7    O
and    O
TBS    O
reprotection    O
(    O
TBSOtf    O
,    O
lutidine    B-Pyridine114692510
)    O
to    O
alcohol    O
2.8    O
it    O
was    O
possible    O
to    O
remove    O
the    O
phenylsulfide    O
group    O
in    O
a    O
with    O
tributyltin    O
hydride    O
and    O
AIBN(see    O
Barton    O
-    O
McCombie    O
deoxygenation    O
)    O
to    O
alcohol    O
2.9    O
.    O

2-Acetylpyridine    B-Pyridine114692510
is    O
an    O
organic    O
compound    O
with    O
the    O
formula    O
CH3COC5H4N.    O
It    O
is    O
a    O
viscous    O
colorless    O
liquid    O
that    O
is    O
widely    O
used    O
as    O
a    O
flavoring    O
substance    O
.    O

SB-243213    B-Pyridine114692510

Ferroin    B-Pyridine114692510
is    O
the    O
chemical    O
compound    O
with    O
the    O
formula    O
[    O
Fe("o    O
"-    O
phen)3]SO4    O
,    O
where    O
"    O
o    O
"-    O
phen    O
is    O
an    O
abbreviation    O
for    O
phenanthroline    B-Pyridine114692510
,    O
a    O
bidentate    O
ligand    O
.    O

The    O
reaction    O
of    O
silicon    O
tetrachloride    O
with    O
an    O
excess    O
of    O
sodium    O
azide    O
at    O
room    O
temperature    O
in    O
acetonitrile    O
will    O
result    O
in    O
the    O
formation    O
of    O
sodium    O
hexaazidosilicide    O
which    O
by    O
adding    O
ligands    O
such    O
as    O
2,2′-bipyridine    O
and    O
phenanthroline    B-Pyridine114692510
will    O
result    O
in    O
stable    O
silicon    O
tetraazide    O
adducts    O
Other    O
bases    O
such    O
as    O
pyridine    O
and    O
tetramethylethylenediamine    O
will    O
not    O
react    O
with    O
the    O
hexaazido    O
silicide    O
ion    O
.    O

The    O
Sonogashira    O
coupling    O
is    O
applied    O
in    O
the    O
synthesis    O
of    O
cross    O
-    O
conjugated    O
oligo(phenylene    O
enynylene)s    O
and    O
phenanthroline    B-Pyridine114692510
derivatives    O
.    O

The    O
interaction    O
of    O
the    O
Grignard    O
reagent    O
with    O
phenanthroline    B-Pyridine114692510
or    O
2,2'-bipyridine    B-Pyridine114692510
causes    O
a    O
color    O
change    O
.    O

The    O
catalyst    O
used    O
is    O
formed    O
from    O
copper(I    O
)    O
iodide    O
and    O
phenanthroline    B-Pyridine114692510
.    O

Several    O
chemical    O
derivatives    O
of    O
camptothecin    O
are    O
under    O
investigation    O
for    O
or    O
used    O
as    O
drugs    O
for    O
cancer    O
treatment    O
,    O
including    O
irinotecan    O
,    O
topotecan    B-Pyridine114692510
,    O
rubitecan    B-Pyridine114692510
.    O

Mepyramine    B-Pyridine114692510
(    O
4-methoxy    O
analog    O
)    O

Pyrilamine    B-Pyridine114692510
maleate    I-Pyridine114692510
15    O
mg    O
(    O
antihistamine    O
)    O

Rifaximin    B-Pyridine114692510
,    O
sold    O
under    O
the    O
trade    O
name    O
Xifaxan    B-Pyridine114692510
among    O
others    O
,    O
is    O
an    O
antibiotic    O
used    O
to    O
treat    O
traveler    O
's    O
diarrhea    O
,    O
irritable    O
bowel    O
syndrome    O
,    O
and    O
hepatic    O
encephalopathy    O
.    O

Rifaximin    B-Pyridine114692510
may    O
also    O
be    O
useful    O
.    O

Rifaximin    B-Pyridine114692510
is    O
approved    O
in    O
the    O
U.S.    O
for    O
treatment    O
of    O
TD    O
caused    O
by    O
ETEC    O
.    O

Some    O
of    O
these    O
calcium    O
antagonists    O
include    O
verapamil    O
,    O
diltiazem    O
,    O
amlodipine    B-Pyridine114692510
,    O
benidipine    O
,    O
cilnidipine    O
,    O
nicardipine    O
,    O
and    O
barnidipine    B-Pyridine114692510
.    O

Pyriprole    B-Pyridine114692510
(    O
trade    O
name    O
Prac-tic    B-Pyridine114692510
)    O
is    O
for    O
veterinary    O
use    O
on    O
dogs    O
against    O
external    O
parasites    O
such    O
as    O
fleas    O
and    O
ticks    O
.    O

MPPF    B-Pyridine114692510

Thus    O
,    O
β-lactams    O
are    O
structural    O
elements    O
of    O
penicillin    O
and    O
cephalosporin    O
antibiotics    O
,    O
imidazoles    O
are    O
found    O
both    O
in    O
modern    O
herbicides    O
,    O
e.g.    O
Arsenal    B-Pyridine114692510
(    O
imazapyr    O
)    O
and    O
pharmaceuticals    O
,    O
e.g.    O
the    O
antiulcerants    O
Tagamet    O
(    O
cimetidine    O
.    O

(1,2,5,6-Tetrahydropyridin-4-yl)methylphosphinic    B-Pyridine114692510
acid    I-Pyridine114692510
(    O
TPMPA    B-Pyridine114692510
)    O
is    O
a    O
GABA    O
antagonist    O
selective    O
for    O
the    O
GABAA-ρ    O
(    O
previously    O
known    O
as    O
GABAC    O
)    O
subtype    O
.    O

Garlon    B-Pyridine114692510
and    O
Tordon    B-Pyridine114692510
and    O
their    O
derivatives    O
have    O
been    O
found    O
to    O
be    O
effective    O
chemical    O
means    O
of    O
control    O
.    O

Specifically    O
,    O
he    O
sought    O
the    O
removal    O
of    O
2,4-D    O
and    O
Garlon    B-Pyridine114692510
4    I-Pyridine114692510
based    O
on    O
concerns    O
regarding    O
potential    O
interaction    O
with    O
the    O
local    O
watershed    O
.    O

Effective    O
(    O
when    O
used    O
with    O
a    O
surfactant    O
)    O
contact    O
herbicides    O
include    O
glyphosate    O
,    O
triclopyr    B-Pyridine114692510
and    O
sulfurometuron    O
-    O
methyl    O
.    O

A    O
systemic    O
herbicide    O
,    O
for    O
example    O
,    O
glyphosate    O
,    O
triclopyr    B-Pyridine114692510
,    O
or    O
picloram    B-Pyridine114692510
,    O
can    O
be    O
applied    O
directly    O
on    O
cut    O
stems    O
,    O
which    O
is    O
an    O
effective    O
means    O
of    O
transporting    O
the    O
herbicide    O
into    O
the    O
kudzu    O
's    O
extensive    O
root    O
system    O
.    O

The    O
tenofovir    O
component    O
of    O
emtricitabine    O
/    O
tenofovir    O
interacts    O
with    O
the    O
following    O
drugs    O
:    O
didanosine    O
,    O
atazanavir    B-Pyridine114692510
,    O
and    O
lopinavir    O
/    O
ritonavir    O
.    O

Atazanavir    B-Pyridine114692510

Drugs    O
that    O
depend    O
on    O
stomach    O
pH    O
for    O
absorption    O
may    O
interact    O
with    O
omeprazole    O
;    O
drugs    O
that    O
depend    O
on    O
an    O
acidic    O
environment    O
(    O
such    O
as    O
ketoconazole    O
or    O
atazanavir    B-Pyridine114692510
)    O
will    O
be    O
poorly    O
absorbed    O
,    O
whereas    O
drugs    O
that    O
are    O
broken    O
down    O
in    O
acidic    O
environments    O
(    O
such    O
as    O
erythromycin    O
)    O
will    O
be    O
absorbed    O
to    O
a    O
greater    O
extent    O
than    O
normal    O
.    O

azamethiphos    B-Pyridine114692510

Chemical    O
control    O
can    O
be    O
achieved    O
with    O
a    O
variety    O
of    O
products    O
including    O
:    O
Clopyralid    B-Pyridine114692510
,    O
glyphosate    O
,    O
Diquat    O
,    O
Picloram    B-Pyridine114692510
,    O
and    O
2    O
,    O
4-D    O
ester    O
.    O

Many    O
chlorinated    O
N    O
-    O
heterocycles    O
are    O
formally    O
imidoyl    O
chlorides    O
,    O
e.g.    O
2-chloropyridine    B-Pyridine114692510
,    O
2    O
,    O
4    O
,    O
and    O
6-chloropyrimidines    O
.    O

Although    O
no    O
MKK1/2    O
or    O
ERK1/2    O
inhibitors    O
were    O
developed    O
for    O
clinical    O
use    O
,    O
kinase    O
inhibitors    O
that    O
also    O
inhibit    O
Raf    O
kinases    O
(    O
e.g.    O
Sorafenib    B-Pyridine114692510
)    O
are    O
successful    O
antineoplastic    O
agents    O
against    O
various    O
types    O
of    O
cancer    O
.    O

sorafenib    B-Pyridine114692510
(    O
protein    O
kinase    O
inhibitor    O
)    O

sorafenib    B-Pyridine114692510
a    O
combined    O
Tyrosine    O
protein    O
kinases    O
inhibitor    O
.    O

sorafenib    B-Pyridine114692510
(    O
tyrosine    O
kinase    O
inhibitor    O
)    O

Sorafenib    B-Pyridine114692510
(    O
Nexavar    O
)    O

In    O
2013    O
some    O
controversy    O
was    O
sparked    O
during    O
a    O
Financial    O
Times    O
panel    O
discussion    O
with    O
relation    O
to    O
Bayer    O
's    O
kidney    O
and    O
liver    O
cancer    O
drug    O
Nexavar    B-Pyridine114692510
.    O

Because    O
most    O
systemic    O
drugs    O
have    O
no    O
efficacy    O
in    O
the    O
treatment    O
of    O
HCC    O
,    O
research    O
into    O
the    O
molecular    O
pathways    O
involved    O
in    O
the    O
production    O
of    O
liver    O
cancer    O
produced    O
sorafenib    B-Pyridine114692510
,    O
a    O
targeted    O
therapy    O
drug    O
that    O
prevents    O
cell    O
proliferation    O
and    O
blood    O
cell    O
growth    O
.    O

Two    O
other    O
harmala    B-Pyridine114692510
alkaloid    I-Pyridine114692510
in    O
"    O
B.    O
caapi    O
"    O
,    O
harmaline    O
and    O
harmine    B-Pyridine114692510
,    O
are    O
reversible    O
inhibitors    O
of    O
monoamine    O
oxidase    O
A.    O
Tetrahydroharmine    O
,    O
however    O
,    O
does    O
not    O
inhibit    O
monoamine    O
oxidase    O
B.    O

In    O
the    O
20th    O
century    O
,    O
the    O
active    O
chemical    O
constituent    O
of    O
"    O
B.    O
caapi    O
"    O
was    O
named    O
"    O
telepathine    B-Pyridine114692510
"    O
,    O
but    O
it    O
was    O
found    O
to    O
be    O
identical    O
to    O
a    O
chemical    O
already    O
isolated    O
from    O
"    O
Peganum    O
harmala    O
"    O
and    O
was    O
given    O
the    O
name    O
harmaline    O
.    O

The    O
three    O
most    O
studied    O
harmala    O
alkaloids    O
in    O
the    O
"    O
B.    O
caapi    O
"    O
vine    O
are    O
harmine    B-Pyridine114692510
,    O
harmaline    O
and    O
tetrahydroharmine    O
.    O

Molecular    O
structure    O
of    O
harmine    B-Pyridine114692510
.    O

In    O
contrast    O
to    O
neonicotinoid    B-Pyridine114692510
such    O
as    O
acetamiprid    B-Pyridine114692510
,    O
clothianidin    B-Pyridine114692510
,    O
imidacloprid    B-Pyridine114692510
,    O
and    O
thiamethoxam    B-Pyridine114692510
,    O
which    O
are    O
absorbed    O
through    O
the    O
skin    O
to    O
some    O
extent    O
,    O
fipronil    O
is    O
not    O
absorbed    O
substantially    O
through    O
the    O
skin    O
.    O

The    O
European    O
Food    O
Safety    O
Authority    O
ruled    O
that    O
three    O
neonicotinoid    B-Pyridine114692510
pesticides    O
(    O
clothianidin    B-Pyridine114692510
,    O
imidacloprid    B-Pyridine114692510
,    O
and    O
thiamethoxam    B-Pyridine114692510
)    O
presented    O
a    O
high    O
risk    O
for    O
bees    O
.    O

As    O
the    O
number    O
of    O
beet    O
leafhoppers    O
continued    O
to    O
rise    O
,    O
the    O
EPA    O
ordered    O
the    O
use    O
of    O
clothianidin    B-Pyridine114692510
to    O
help    O
control    O
the    O
insects    O
in    O
2006    O
,    O
2007    O
and    O
2008    O
.    O

Co    O
-    O
administration    O
of    O
atorvastatin    O
with    O
one    O
of    O
CYP3A4    O
inhibitors    O
such    O
as    O
itraconazole    O
,    O
telithromycin    B-Pyridine114692510
,    O
and    O
voriconazole    O
,    O
may    O
increase    O
serum    O
concentrations    O
of    O
atorvastatin    O
,    O
which    O
may    O
lead    O
to    O
adverse    O
reactions    O
.    O

Ketek    B-Pyridine114692510
(    O
Sanofi    O
-    O
Aventis    O
)    O
redirects    O
to    O
"    O
telithromycin    B-Pyridine114692510
"    O

Caution    O
should    O
be    O
exercised    O
when    O
aliskiren    O
is    O
administered    O
with    O
ketoconazole    O
or    O
other    O
moderate    O
P    O
-    O
glycoprotein    O
inhibitors    O
(    O
itraconazole    O
,    O
clarithromycin    O
,    O
telithromycin    B-Pyridine114692510
,    O
erythromycin    O
,    O
or    O
amiodarone    O
)    O
.    O

One    O
noteworthy    O
derivative    O
is    O
Crabtree's    B-Pyridine114692510
catalyst    I-Pyridine114692510
,    O
a    O
homogeneous    O
catalyst    O
for    O
hydrogenation    O
reactions    O
.    O

However    O
,    O
there    O
is    O
evidence    O
in    O
literature    O
,    O
in    O
which    O
a    O
propargyl    O
alcohol    O
's    O
alkyne    O
was    O
reduced    O
in    O
presence    O
of    O
a    O
vinyl    O
iodide    O
using    O
hydrogen    O
over    O
Pd    O
/    O
CaCO3    O
or    O
Crabtree's    B-Pyridine114692510
catalyst    I-Pyridine114692510
.    O

Compounds    O
which    O
increased    O
"    O
SMN2    O
"    O
activity    O
"    O
in    O
vitro    O
"    O
but    O
did    O
not    O
make    O
it    O
to    O
the    O
clinical    O
stage    O
include    O
growth    O
hormone    O
,    O
various    O
histone    O
deacetylase    O
inhibitors    O
,    O
benzamide    O
M344    O
,    O
hydroxamic    O
acids    O
(    O
CBHA    O
,    O
SBHA    O
,    O
entinostat    B-Pyridine114692510
,    O
panobinostat    O
,    O
trichostatin    O
A    O
,    O
vorinostat    O
)    O
,    O
prolactin    O
as    O
well    O
as    O
natural    O
polyphenol    O
compounds    O
like    O
resveratrol    O
and    O
curcumin    O
.    O

entinostat    B-Pyridine114692510
(    O
INN    O
)    O

Sazetidine    B-Pyridine114692510
A    I-Pyridine114692510
(    O
AMOP-H-OH    B-Pyridine114692510
)    O
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
subtype    O
selective    O
partial    O
agonist    O
at    O
α4β2    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
,    O
acting    O
as    O
an    O
agonist    O
at    O
(    O
α4)2(β2)3    O
pentamers    O
,    O
but    O
as    O
an    O
antagonist    O
at    O
(    O
α4)3(β2)2    O
pentamers    O
.    O

The    O
latter    O
two    O
(    O
axitinib    B-Pyridine114692510
and    O
pazopanib    O
)    O
are    O
in    O
clinical    O
trials    O
.    O

Axitinib    B-Pyridine114692510
,    O
a    O
drug    O
used    O
to    O
treat    O
renal    O
cell    O
carcinoma    O
,    O
has    O
been    O
shown    O
to    O
be    O
effective    O
at    O
inhibiting    O
the    O
Abl    O
kinase    O
activity    O
in    O
patients    O
with    O
BCR    O
-    O
ABL1(T315I    O
)    O
.    O

Piclozotan    B-Pyridine114692510

Picotamide    B-Pyridine114692510
has    O
activity    O
both    O
as    O
a    O
thromboxane    O
synthase    O
inhibitor    O
and    O
as    O
a    O
thromboxane    O
receptor    O
antagonist    O
.    O

Pyritinol    B-Pyridine114692510
:    O
A    O
1973    O
study    O
found    O
that    O
large    O
doses    O
(    O
several    O
hundred    O
times    O
the    O
recommended    O
daily    O
intake    O
)    O
of    O
Pyritinol    O
,    O
a    O
synthetic    O
Vitamin    O
B6    O
analog    O
,    O
can    O
help    O
to    O
reduce    O
hangover    O
symptoms    O
.    O

Fenyramidol    B-Pyridine114692510

AZD0328    B-Pyridine114692510
is    O
an    O
experimental    O
drug    O
.    O

Examples    O
include    O
the    O
Collins    B-Pyridine114692510
reagent    I-Pyridine114692510
,    O
Fenton    O
's    O
reagent    O
,    O
and    O
Grignard    O
reagents    O
.    O

These    O
include    O
Collins    B-Pyridine114692510
reagent    I-Pyridine114692510
and    O
pyridinium    B-Pyridine114692510
chlorochromate    I-Pyridine114692510
.    O

Chromium(III    O
)    O
is    O
a    O
hard    O
lewis    O
acid    O
and    O
as    O
such    O
has    O
high    O
affinity    O
to    O
the    O
carboxylate    O
oxygen    O
and    O
medium    O
affinity    O
to    O
the    O
pyridine    O
nitrogen    O
of    O
picolinate    B-Pyridine114692510
.    O

Unlike    O
the    O
Cr(VI    O
)    O
complexes    O
however    O
,    O
it    O
was    O
thought    O
that    O
these    O
carcinogenic    O
effects    O
were    O
due    O
to    O
picolinic    B-Pyridine114692510
acid    I-Pyridine114692510
itself    O
,    O
and    O
not    O
the    O
metal    O
ion    O
.    O

Bearers    O
of    O
this    O
SNP    O
may    O
or    O
may    O
not    O
show    O
increased    O
risk    O
of    O
developing    O
acute    O
gastrointestinal    O
bleeding    O
during    O
the    O
use    O
of    O
non    O
-    O
steroidal    O
anti    O
-    O
inflammatory    O
drugs    O
(    O
NSAIDs    O
)    O
that    O
are    O
its    O
substrates    O
such    O
as    O
aceclofenac    O
,    O
celecoxib    O
,    O
diclofenac    O
,    O
ibuprofen    O
,    O
indomethacin    O
,    O
lornoxicam    B-Pyridine114692510
,    O
meloxicam    O
,    O
naproxen    O
,    O
piroxicam    O
,    O
tenoxicam    B-Pyridine114692510
,    O
and    O
valdecoxib    O
.    O

Pyrinuron    B-Pyridine114692510
(    O
an    O
urea    O
derivative    O
)    O

2-Pyridylethylamine    B-Pyridine114692510

MK-9470    B-Pyridine114692510
is    O
a    O
synthetic    O
compound    O
,    O
which    O
binds    O
to    O
the    O
CB1    O
cannabinoid    O
receptor    O
and    O
functions    O
as    O
an    O
inverse    O
agonist    O
.    O

In    O
canines    O
,    O
topical    O
imidacloprid    B-Pyridine114692510
with    O
moxidectin    O
,    O
or    O
milbemycin    O
oxime    O
(    O
Interceptor    O
)    O
have    O
been    O
recommended    O
.    O

Other    O
sources    O
have    O
reported    O
positive    O
results    O
treating    O
dogs    O
with    O
moxidectin    O
,    O
imidacloprid    B-Pyridine114692510
,    O
or    O
milbemycin    O
oxime    O
.    O

Experiments    O
have    O
shown    O
that    O
it    O
can    O
be    O
controlled    O
using    O
the    O
insecticide    O
imidacloprid    B-Pyridine114692510
.    O

Imidacloprid    B-Pyridine114692510
is    O
a    O
systemic    O
insecticide    O
that    O
acts    O
as    O
an    O
insect    O
neurotoxin    O
and    O
belongs    O
to    O
a    O
class    O
of    O
chemicals    O
called    O
the    O
neonicotinoids    B-Pyridine114692510
which    O
act    O
on    O
the    O
central    O
nervous    O
system    O
of    O
insects    O
,    O
with    O
much    O
lower    O
toxicity    O
to    O
mammals    O
.    O

In    O
contrast    O
to    O
neonicotinoid    B-Pyridine114692510
such    O
as    O
acetamiprid    B-Pyridine114692510
,    O
clothianidin    B-Pyridine114692510
,    O
imidacloprid    B-Pyridine114692510
,    O
and    O
thiamethoxam    B-Pyridine114692510
,    O
which    O
are    O
absorbed    O
through    O
the    O
skin    O
to    O
some    O
extent    O
,    O
fipronil    O
is    O
not    O
absorbed    O
substantially    O
through    O
the    O
skin    O
.    O

Imidacloprid    B-Pyridine114692510

The    O
European    O
Food    O
Safety    O
Authority    O
ruled    O
that    O
three    O
neonicotinoid    B-Pyridine114692510
pesticides    O
(    O
clothianidin    B-Pyridine114692510
,    O
imidacloprid    B-Pyridine114692510
,    O
and    O
thiamethoxam    B-Pyridine114692510
)    O
presented    O
a    O
high    O
risk    O
for    O
bees    O
.    O

mosapramine    B-Pyridine114692510
(    O
INN    O
)    O

For    O
example    O
,    O
fenitrothion    O
,    O
malathion    O
,    O
acetamiprid    B-Pyridine114692510
,    O
and    O
thiacloprid    B-Pyridine114692510
.    O

Obidoxime    B-Pyridine114692510
is    O
a    O
member    O
of    O
the    O
oxime    O
family    O
used    O
to    O
treat    O
nerve    O
gas    O
poisoning    O
.    O

5-ASA    O
compounds    O
,    O
such    O
as    O
mesalazine    O
and    O
sulfasalazine    B-Pyridine114692510
,    O
have    O
shown    O
to    O
be    O
of    O
very    O
little    O
efficacy    O
in    O
the    O
treatment    O
of    O
Crohn    O
's    O
disease    O
,    O
either    O
for    O
induction    O
or    O
for    O
maintenance    O
of    O
remission    O
.    O

Additional    O
treatments    O
include    O
retinoids    O
,    O
such    O
as    O
acitretin    O
,    O
or    O
sulfasalazine    B-Pyridine114692510
.    O

Mesalazine    O
is    O
the    O
active    O
moiety    O
of    O
sulfasalazine    B-Pyridine114692510
,    O
which    O
is    O
metabolized    O
to    O
sulfapyridine    O
and    O
mesalazine    O
.    O

It    O
has    O
also    O
been    O
used    O
as    O
a    O
second    O
line    O
agent    O
to    O
sulfasalazine    B-Pyridine114692510
in    O
people    O
with    O
inflammatory    O
bowel    O
disease    O
such    O
as    O
ulcerative    O
colitis    O
and    O
Crohn    O
's    O
disease    O
.    O

PAS    O
has    O
also    O
been    O
used    O
in    O
the    O
treatment    O
of    O
inflammatory    O
bowel    O
disease    O
(    O
ulcerative    O
colitis    O
and    O
Crohn    O
's    O
disease    O
)    O
,    O
but    O
has    O
been    O
superseded    O
by    O
other    O
drugs    O
such    O
as    O
sulfasalazine    B-Pyridine114692510
and    O
mesalazine    O
.    O

Displacement    O
of    O
the    O
halogen    O
by    O
picoline    B-Pyridine114692510
gives    O
amprolium    O
.    O

They    O
found    O
that    O
aluminum    O
chloride    O
could    O
only    O
dissolve    O
in    O
methylene    O
chloride    O
in    O
the    O
presence    O
of    O
the    O
adduct    O
of    O
4-picoline    B-Pyridine114692510
and    O
boron    O
trichloride    O
.    O

Picoline    B-Pyridine114692510
refers    O
to    O
three    O
different    O
methylpyridine    O
isomers    O
,    O
all    O
with    O
the    O
chemical    O
formula    O
C6H7N    O
and    O
a    O
molar    O
mass    O
of    O
93.13    O
g    O
mol−1    O
.    O

Picoplatin    B-Pyridine114692510

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
1-(4-amino-2-methylpyrimid-5-ylmethyl)-3-(beta    O
-    O
hydroxyethyl)-2-    O
,    O
methylpyridinium    B-Pyridine114692510
bromide    I-Pyridine114692510
,    O
and    O
H2O    O
,    O
whereas    O
its    O
3    O
products    O
are    O
1-(4-hydroxy-2-methylpyrimid-5-ylmethyl)-3-(beta    O
-    O
hydroxyethyl)-2-    O
,    O
methylpyridinium    B-Pyridine114692510
bromide    I-Pyridine114692510
,    O
and    O
NH3    O
.    O

In    O
1982    O
,    O
seven    O
people    O
in    O
Santa    O
Clara    O
County    O
,    O
California    O
were    O
diagnosed    O
with    O
Parkinsonism    O
after    O
having    O
used    O
MPPP    O
contaminated    O
with    O
MPTP    B-Pyridine114692510
.    O

In    O
addition    O
,    O
recent    O
evidence    O
shows    O
that    O
inhibition    O
of    O
SIRT2    O
protects    O
against    O
MPTP    B-Pyridine114692510
-    O
induced    O
neuronal    O
loss    O
in    O
vivo    O
.    O

It    O
is    O
unlikely    O
that    O
the    O
tetrahydropyridine    O
byproducts    O
that    O
may    O
be    O
formed    O
during    O
the    O
synthesis    O
of    O
PEPAP    O
are    O
neurotoxic    O
in    O
the    O
same    O
way    O
as    O
the    O
MPPP    O
byproduct    O
MPTP    B-Pyridine114692510
.    O

Omigapil    O
also    O
rescues    O
rat    O
oligodendrocytes    O
from    O
AMPA    O
receptor    O
excitotoxicity    O
and    O
rat    O
embryonic    O
mesencephalic    O
(    O
midbrain    O
)    O
dopaminergic    O
cells    O
from    O
toxicity    O
by    O
MPP+/MPTP    B-Pyridine114692510
.    O

The    O
appearance    O
of    O
parkinsonism    O
in    O
a    O
group    O
of    O
drug    O
addicts    O
in    O
the    O
early    O
1980s    O
who    O
consumed    O
a    O
contaminated    O
batch    O
of    O
the    O
synthetic    O
opiate    O
MPPP    O
led    O
to    O
the    O
discovery    O
of    O
the    O
chemical    O
MPTP    B-Pyridine114692510
as    O
an    O
agent    O
that    O
causes    O
parkinsonism    O
in    O
non    O
-    O
human    O
primates    O
as    O
well    O
as    O
in    O
humans    O
.    O

At    O
NIMH    O
,    O
he    O
came    O
up    O
with    O
the    O
false    O
neurotransmitter    O
theory    O
to    O
explain    O
the    O
action    O
of    O
drugs    O
such    O
as    O
monoamine    O
oxidase    O
inhibitors    O
,    O
and    O
studied    O
the    O
relationship    O
between    O
the    O
neurotoxin    O
MPTP    B-Pyridine114692510
and    O
Parkinson    O
's    O
disease    O
.    O

Aconiazide    B-Pyridine114692510
is    O
an    O
anti    O
-    O
tuberculosis    O
prodrug    O
.    O

File    O
:    O
Ronifibrate    B-Pyridine114692510

Five    O
agents    O
were    O
in    O
clinical    O
trials    O
in    O
2002    O
:    O
raltitrexed    O
,    O
pemetrexed    O
,    O
nolatrexed    B-Pyridine114692510
,    O
ZD9331    O
,    O
and    O
GS7904L.    O

WAY-100,635    B-Pyridine114692510

The    O
neurogenesis    O
appears    O
to    O
be    O
mediated    O
by    O
activation    O
of    O
the    O
5-HT1A    O
receptor    O
,    O
as    O
co    O
-    O
administration    O
with    O
the    O
5-HT1A    O
antagonist    O
WAY-100,635    B-Pyridine114692510
abolished    O
the    O
effect    O
.    O

Recently    O
selective    O
phosphodiesterase    O
4    O
(    O
PDE4    O
)    O
inhibitors    O
like    O
apremilast    O
(    O
a    O
thalidomide    O
derivative    O
)    O
,    O
roflumilast    B-Pyridine114692510
,    O
and    O
the    O
less    O
subtype    O
-    O
selective    O
PDE4    O
inhibitor    O
,    O
pentoxifylline    O
,    O
have    O
been    O
tried    O
as    O
a    O
treatment    O
for    O
sarcoidosis    O
,    O
with    O
successful    O
results    O
being    O
obtained    O
with    O
apremilast    O
in    O
cutaneous    O
sarcoidosis    O
in    O
a    O
small    O
open    O
-    O
label    O
study    O
.    O

roflumilast    B-Pyridine114692510
(    O
antiinflammatory    O
)    O
–    O
inhibits    O
PDE4A    O
isoforms    O
1    O
,    O
2    O
,    O
and    O
6    O

gevotroline    B-Pyridine114692510
(    O
INN    O
)    O

It    O
was    O
developed    O
as    O
a    O
less    O
toxic    O
analogue    O
of    O
the    O
potent    O
poison    O
dart    O
frog    O
-    O
derived    O
compound    O
epibatidine    B-Pyridine114692510
,    O
which    O
is    O
some    O
200x    O
stronger    O
than    O
morphine    O
as    O
an    O
analgesic    O
but    O
produces    O
extremely    O
dangerous    O
toxic    O
side    O
effects    O
.    O

It    O
was    O
developed    O
as    O
a    O
less    O
toxic    O
analogue    O
of    O
the    O
potent    O
frog    O
-    O
derived    O
alkaloid    O
epibatidine    B-Pyridine114692510
,    O
which    O
is    O
around    O
200    O
times    O
stronger    O
than    O
morphine    O
as    O
an    O
analgesic    O
but    O
produces    O
extremely    O
dangerous    O
toxic    O
nicotinic    O
side    O
effects    O
.    O

Intraocular    O
injections    O
of    O
epibatidine    B-Pyridine114692510
,    O
a    O
cholinergic    O
agonist    O
,    O
can    O
be    O
used    O
to    O
block    O
spontaneous    O
firing    O
in    O
half    O
of    O
all    O
retinal    O
ganglion    O
cells    O
and    O
cause    O
uncorrelated    O
firing    O
in    O
the    O
remaining    O
half    O
.    O

The    O
resulting    O
brew    O
may    O
contain    O
the    O
powerful    O
psychedelic    O
drug    O
DMT    O
and    O
MAO    O
inhibiting    O
harmala    B-Pyridine114692510
alkaloid    I-Pyridine114692510
,    O
which    O
are    O
necessary    O
to    O
make    O
the    O
DMT    O
orally    O
active    O
.    O

Natural    O
variations    O
in    O
plant    O
alkaloid    O
content    O
and    O
profiles    O
also    O
affect    O
the    O
final    O
concentration    O
of    O
alkaloids    O
in    O
the    O
brew    O
,    O
and    O
the    O
physical    O
act    O
of    O
cooking    O
may    O
also    O
serve    O
to    O
modify    O
the    O
alkaloid    O
profile    O
of    O
harmala    B-Pyridine114692510
alkaloids    O
.    O

However    O
,    O
evidence    O
indicates    O
that    O
harmala    B-Pyridine114692510
alkaloids    I-Pyridine114692510
act    O
only    O
on    O
MAO    O
-    O
A    O
,    O
in    O
a    O
reversible    O
way    O
similar    O
to    O
moclobemide    O
(    O
an    O
antidepressant    O
that    O
does    O
not    O
require    O
dietary    O
restrictions    O
)    O
.    O

Harmala    B-Pyridine114692510
alkaloid    I-Pyridine114692510
are    O
MAO    O
-    O
inhibiting    O
"    O
beta    O
"-    O
carbolines    O
.    O

The    O
toxin    O
orellanine    B-Pyridine114692510
was    O
later    O
recovered    O
from    O
the    O
species    O
.    O

Moser    O
was    O
also    O
interested    O
in    O
the    O
toxicity    O
of    O
the    O
Agaricales    O
,    O
and    O
was    O
—    O
with    O
his    O
students    O
—    O
involved    O
with    O
research    O
on    O
the    O
toxin    O
orellanine    B-Pyridine114692510
.    O

ABT-670    B-Pyridine114692510
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
potent    O
,    O
orally    O
bioavailable    O
dopamine    O
agonist    O
selective    O
for    O
the    O
D4    O
subtype    O
,    O
which    O
was    O
developed    O
as    O
a    O
possible    O
treatment    O
for    O
erectile    O
dysfunction    O
,    O
although    O
its    O
current    O
uses    O
are    O
limited    O
to    O
scientific    O
research    O
.    O

Immethridine    B-Pyridine114692510
is    O
a    O
histamine    O
agonist    O
selective    O
for    O
the    O
H3    O
subtype    O
.    O

milameline    B-Pyridine114692510
(    O
INN    O
)    O

Epelsiban    B-Pyridine114692510
(    O
INN    O
,    O
USAN    O
,    O
code    O
name    O
GSK-557,296-B    B-Pyridine114692510
)    O
is    O
an    O
orally    O
bioavailable    O
drug    O
which    O
acts    O
as    O
oxytocin    O
receptor    O
antagonist    O
.    O

These    O
include    O
Collins    B-Pyridine114692510
reagent    I-Pyridine114692510
and    O
pyridinium    B-Pyridine114692510
chlorochromate    I-Pyridine114692510
.    O

(    O
This    O
general    O
reaction    O
was    O
probably    O
first    O
found    O
in    O
the    O
steroids    O
and    O
bore    O
the    O
name    O
of    O
"    O
"    O
i    O
"-    O
steroid    O
rearrangement    O
.    O
"    O
)    O
Oxidation    O
of    O
the    O
product    O
by    O
means    O
of    O
PCC    B-Pyridine114692510
affords    O
the    O
ketone    O
.    O

Pyridinium    B-Pyridine114692510
chlorochromate    I-Pyridine114692510

More    O
selective    O
or    O
gentler    O
oxidizing    O
reagents    O
include    O
pyridinium    B-Pyridine114692510
chlorochromate    I-Pyridine114692510
(    O
PCC    O
)    O
and    O
pyridinium    B-Pyridine114692510
dichromate    I-Pyridine114692510
(    O
PDC    O
)    O
.    O

Isoguvacine    B-Pyridine114692510
is    O
a    O
GABAA    O
receptor    O
agonist    O
used    O
in    O
scientific    O
research    O
.    O

dexbrompheniramine    B-Pyridine114692510
(    O
INN    O
)    O

Disomer    B-Pyridine114692510

Tripelennamine    B-Pyridine114692510
,    O
sold    O
under    O
the    O
brand    O
name    O
Pyribenzamine    B-Pyridine114692510
by    O
Novartis    O
,    O
is    O
a    O
drug    O
that    O
is    O
used    O
as    O
an    O
antipruritic    O
and    O
first    O
-    O
generation    O
antihistamine    O
.    O

In    O
the    O
1970s    O
,    O
recreational    O
drug    O
users    O
discovered    O
that    O
combining    O
pentazocine    O
with    O
tripelennamine    B-Pyridine114692510
(    O
a    O
first    O
-    O
generation    O
ethylenediamine    O
antihistamine    O
most    O
commonly    O
dispensed    O
under    O
the    O
brand    O
names    O
Pelamine    O
and    O
Pyribenzamine    O
)    O
produced    O
a    O
euphoric    O
sensation    O
.    O

Other    O
agents    O
directly    O
potentiate    O
the    O
effects    O
of    O
analgesics    O
,    O
such    O
as    O
using    O
hydroxyzine    O
,    O
promethazine    O
,    O
carisoprodol    O
,    O
or    O
tripelennamine    B-Pyridine114692510
to    O
increase    O
the    O
pain    O
-    O
killing    O
ability    O
of    O
a    O
given    O
dose    O
of    O
opioid    O
analgesic    O
.    O

Pozanicline    B-Pyridine114692510
(    O
INN    O
,    O
codenamed    O
ABT-089    B-Pyridine114692510
)    O
is    O
a    O
drug    O
developed    O
by    O
Abbott    O
,    O
that    O
has    O
nootropic    O
and    O
neuroprotective    O
effects    O
.    O

Adipiplon    B-Pyridine114692510

It    O
is    O
also    O
a    O
known    O
precursor    O
to    O
S-15535    O
&    O
Lecozotan    B-Pyridine114692510
.    O

CP-226,269    B-Pyridine114692510
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
dopamine    O
agonist    O
selective    O
for    O
the    O
D4    O
subtype    O
,    O
which    O
is    O
used    O
for    O
researching    O
the    O
role    O
of    O
D4    O
receptors    O
in    O
the    O
brain    O
.    O

Aldrithiol-2    B-Pyridine114692510

Ocinaplon    B-Pyridine114692510
for    O
anxiety    O
disorders    O
.    O

Torsemide    B-Pyridine114692510

For    O
nonresponders    O
,    O
a    O
loop    O
diuretic    O
may    O
also    O
be    O
added    O
and    O
generally    O
,    O
furosemide    O
is    O
added    O
at    O
a    O
dose    O
of    O
40    O
mg    O
/    O
day    O
(    O
max    O
160    O
mg    O
/    O
day    O
)    O
,    O
or    O
alternatively    O
(    O
bumetanide    O
or    O
torasemide    B-Pyridine114692510
)    O
.    O

During    O
development    O
it    O
was    O
known    O
as    O
FE200486    B-Pyridine114692510
.    O

The    O
major    O
active    O
ingredients    O
of    O
the    O
sugar    O
-    O
free    O
lozenges    O
are    O
cetylpyridinium    B-Pyridine114692510
chloride    I-Pyridine114692510
,    O
benzocaine    O
(    O
which    O
produces    O
the    O
numbing    O
sensation    O
)    O
,    O
and    O
menthol    O
.    O

CPC    O
containing    O
mouthwash    O
contains    O
cetyl    B-Pyridine114692510
pyridinium    I-Pyridine114692510
chloride    I-Pyridine114692510
,    O
found    O
in    O
brands    O
such    O
as    O
Colgate    O
Plax    O
,    O
Crest    O
Pro    O
Health    O
,    O
Oral    O
B    O
Pro    O
Health    O
Rinse    O
.    O

Alternatively    O
,    O
anionic    O
surfactants    O
such    O
as    O
sodium    O
lauryl    O
sulfate    O
can    O
be    O
titrated    O
with    O
cetyl    B-Pyridine114692510
pyridinium    I-Pyridine114692510
chloride    I-Pyridine114692510
.    O

Ampiroxicam    B-Pyridine114692510

17α-Hydroxylase/17,20-lyase    O
(    O
CYP17A1    O
)    O
inhibitors    O
such    O
as    O
abiraterone    B-Pyridine114692510
acetate    I-Pyridine114692510
,    O
etomidate    O
,    O
galeterone    O
,    O
ketoconazole    O
,    O
and    O
orteronel    O
inhibit    O
the    O
production    O
of    O
androgens    O
and    O
glucocorticoids    O
and    O
are    O
used    O
to    O
reduce    O
androgen    O
levels    O
in    O
the    O
treatment    O
of    O
prostate    O
cancer    O
.    O

Although    O
spironolactone    O
is    O
said    O
to    O
be    O
a    O
relatively    O
weak    O
inhibitor    O
of    O
17α-hydroxylase    O
and    O
17,20-lyase    O
,    O
at    O
least    O
compared    O
to    O
more    O
potent    O
steroidogenesis    O
inhibitors    O
like    O
ketoconazole    O
and    O
abiraterone    B-Pyridine114692510
acetate    I-Pyridine114692510
(    O
which    O
are    O
able    O
to    O
reduce    O
testosterone    O
concentrations    O
to    O
castrate    O
levels    O
)    O
,    O
this    O
action    O
is    O
considered    O
to    O
contribute    O
a    O
significant    O
portion    O
of    O
the    O
antiandrogen    O
effects    O
of    O
spironolactone    O
,    O
for    O
instance    O
lowering    O
testosterone    O
levels    O
in    O
women    O
with    O
hyperandrogenism    O
and    O
in    O
transgender    O
women    O
.    O

The    O
drug    O
abiraterone    B-Pyridine114692510
acetate    I-Pyridine114692510
,    O
which    O
is    O
used    O
to    O
treat    O
castration    O
-    O
resistant    O
prostate    O
cancer    O
,    O
blocks    O
the    O
biosynthesis    O
of    O
androgens    O
by    O
inhibiting    O
the    O
CYP17A1    O
enzyme    O
.    O

2-Mercaptopyridine    B-Pyridine114692510

Naphthylvinylpyridine    B-Pyridine114692510
(    O
NVP    O
)    O
is    O
a    O
naphthalene    O
derivative    O
that    O
possesses    O
anticholinergic    O
activity    O
similar    O
to    O
that    O
of    O
atropine    O
.    O

The    O
company    O
's    O
products    O
include    O
Botox    O
,    O
Namenda    O
,    O
Restasis    O
,    O
Linzess    O
,    O
Bystolic    O
,    O
Juvederm    O
,    O
Latisse    O
,    O
Lo    O
Loestrin    O
Fe    O
,    O
Estrace    O
,    O
Teflaro    B-Pyridine114692510
,    O
Dalvance    O
,    O
Ozurdex    O
,    O
Optive    O
,    O
Natrelle    O
,    O
Viibryd    O
,    O
Liletta    O
,    O
Saphris    O
,    O
Enablex    O
,    O
Actonel    B-Pyridine114692510
,    O
Androderm    O
,    O
Gelnique    O
and    O
others    O
.    O

The    O
agents    O
that    O
are    O
used    O
include    O
daptomycin    O
,    O
linezolid    O
,    O
telavancin    O
,    O
ceftaroline    B-Pyridine114692510
,    O
quinupristin    O
–    O
dalfopristin    O
.    O

Other    O
members    O
of    O
this    O
class    O
have    O
entered    O
development    O
,    O
such    O
as    O
posizolid    B-Pyridine114692510
(    O
AZD2563    O
)    O
,    O
ranbezolid    O
(    O
RBx    O
7644    O
)    O
,    O
torezolid    B-Pyridine114692510
(    O
TR-701    O
)    O
,    O
and    O
radezolid    O
(    O
RX-1741    O
)    O
.    O

Tedizolid    B-Pyridine114692510
is    O
an    O
oxazolidinone    O
antibiotic    O
developed    O
by    O
Dong    O
-    O
A    O
ST    O
,    O
the    O
specialty    O
pharmaceuticals    O
arm    O
of    O
Dong    O
-    O
A    O
Socio    O
Holdings    O
,    O
to    O
treat    O
patients    O
with    O
acute    O
bacterial    O
skin    O
and    O
skin    O
structure    O
infections    O
.    O

3-Hydroxy    B-Pyridine114692510
picolinic    I-Pyridine114692510
acid    I-Pyridine114692510
is    O
a    O
picolinic    B-Pyridine114692510
acid    I-Pyridine114692510
derivative    O
and    O
is    O
a    O
member    O
of    O
the    O
pyridine    O
family    O
.    O

In    O
2011    O
An    O
FDA    O
panel    O
voted    O
unanimously    O
to    O
recommend    O
approval    O
of    O
florbetapir    B-Pyridine114692510
,    O
which    O
is    O
currently    O
used    O
in    O
an    O
investigational    O
study    O
.    O

:    O
N07XX03    O
Xaliproden    B-Pyridine114692510

For    O
example    O
,    O
2-methylpyridine    B-Pyridine114692510
,    O
4-methylpyridine    B-Pyridine114692510
and    O
2-ethyl-5-methylpyridine    O
exhibit    O
widespread    O
use    O
in    O
syntheses    O
of    O
latexes    O
,    O
ion    O
-    O
exchange    O
matrixes    O
,    O
and    O
photography    O
materials    O
.    O

Nitrapyrin    O
is    O
commonly    O
produced    O
by    O
the    O
photochlorination    O
of    O
2-methylpyridine    B-Pyridine114692510
:    O

TC-1698    B-Pyridine114692510
is    O
a    O
drug    O
developed    O
by    O
Targacept    O
which    O
acts    O
as    O
a    O
partial    O
agonist    O
for    O
the    O
α7    O
subtype    O
of    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

Imidacloprid    B-Pyridine114692510
is    O
a    O
systemic    O
insecticide    O
that    O
acts    O
as    O
an    O
insect    O
neurotoxin    O
and    O
belongs    O
to    O
a    O
class    O
of    O
chemicals    O
called    O
the    O
neonicotinoids    B-Pyridine114692510
which    O
act    O
on    O
the    O
central    O
nervous    O
system    O
of    O
insects    O
,    O
with    O
much    O
lower    O
toxicity    O
to    O
mammals    O
.    O

Imidacloprid    O
is    O
a    O
systemic    O
chloronicotinyl    O
pesticide    O
,    O
belonging    O
to    O
the    O
class    O
of    O
neonicotinoid    B-Pyridine114692510
insecticides    O
.    O

Neonicotinoid    B-Pyridine114692510

In    O
2001    O
,    O
the    O
United    O
States    O
Patent    O
and    O
Trademark    O
Office    O
ruled    O
in    O
favor    O
of    O
Syngenta    O
which    O
had    O
filed    O
a    O
suit    O
against    O
Bayer    O
for    O
patent    O
infringement    O
on    O
a    O
class    O
of    O
neonicotinoid    B-Pyridine114692510
insecticides    O
.    O

In    O
contrast    O
to    O
neonicotinoid    B-Pyridine114692510
such    O
as    O
acetamiprid    B-Pyridine114692510
,    O
clothianidin    B-Pyridine114692510
,    O
imidacloprid    B-Pyridine114692510
,    O
and    O
thiamethoxam    B-Pyridine114692510
,    O
which    O
are    O
absorbed    O
through    O
the    O
skin    O
to    O
some    O
extent    O
,    O
fipronil    O
is    O
not    O
absorbed    O
substantially    O
through    O
the    O
skin    O
.    O

In    O
Japan    O
,    O
the    O
insecticide    O
to    O
the    O
sawyers    O
use    O
organophosphorus    O
compound    O
or    O
neonicotinoid    B-Pyridine114692510
.    O

The    O
European    O
Food    O
Safety    O
Authority    O
ruled    O
that    O
three    O
neonicotinoid    B-Pyridine114692510
pesticides    O
(    O
clothianidin    B-Pyridine114692510
,    O
imidacloprid    B-Pyridine114692510
,    O
and    O
thiamethoxam    B-Pyridine114692510
)    O
presented    O
a    O
high    O
risk    O
for    O
bees    O
.    O

Moreover    O
,    O
the    O
findings    O
would    O
explain    O
why    O
other    O
NMDA    O
receptor    O
antagonists    O
such    O
as    O
memantine    O
,    O
lanicemine    B-Pyridine114692510
,    O
and    O
traxoprodil    O
have    O
thus    O
far    O
failed    O
to    O
demonstrate    O
ketamine    O
-    O
like    O
antidepressant    O
effects    O
in    O
human    O
clinical    O
trials    O
.    O

As    O
of    O
2013    O
,    O
other    O
NMDA    O
receptor    O
antagonists    O
in    O
clinical    O
trials    O
for    O
depression    O
included    O
lanicemine    B-Pyridine114692510
,    O
S    O
-    O
ketamine    O
,    O
and    O
GLYX-13    O
,    O
with    O
lancemine    O
being    O
the    O
most    O
advanced    O
.    O

amprolium    B-Pyridine114692510

Amprolium    B-Pyridine114692510
(    O
INN    O
,    O
trade    O
names    O
Amprovine    B-Pyridine114692510
,    O
Amprolium    B-Pyridine114692510
,    O
Amprol    B-Pyridine114692510
,    O
Anticoccid    B-Pyridine114692510
)    O
is    O
a    O
coccidiostat    O
used    O
in    O
poultry    O
.    O

Other    O
members    O
of    O
this    O
class    O
have    O
entered    O
development    O
,    O
such    O
as    O
posizolid    B-Pyridine114692510
(    O
AZD2563    O
)    O
,    O
ranbezolid    O
(    O
RBx    O
7644    O
)    O
,    O
torezolid    B-Pyridine114692510
(    O
TR-701    O
)    O
,    O
and    O
radezolid    O
(    O
RX-1741    O
)    O
.    O

Difenpiramide    B-Pyridine114692510
is    O
a    O
non    O
-    O
steroidal    O
anti    O
-    O
inflammatory    O
drug    O
.    O

VUAA1    B-Pyridine114692510
is    O
a    O
chemical    O
compound    O
that    O
works    O
by    O
over    O
activating    O
an    O
insect    O
's    O
olfactory    O
senses    O
causing    O
a    O
repellent    O
effect    O
.    O

menabitan    B-Pyridine114692510
(    O
INN    O
)    O

Dithiopyr    B-Pyridine114692510
is    O
a    O
preemergent    O
herbicide    O
for    O
crabgrass    O
control    O
in    O
turf    O
and    O
ornamental    O
grasses    O
.    O

Then    O
,    O
acylation    O
of    O
the    O
C4    O
hydroxyl    O
group    O
(    O
acetic    O
anhydride    O
,    O
DMAP    B-Pyridine114692510
,    O
pyridine    O
)    O
resulted    O
in    O
acetate    O
49    O
.    O

In    O
the    O
final    O
synthetic    O
steps    O
(    O
"    O
scheme    O
8    O
''    O
)    O
the    O
amide    O
tail    O
62    O
was    O
added    O
to    O
ABCD    O
ring    O
52    O
in    O
an    O
esterfication    O
catalysed    O
by    O
o    O
,    O
o'-di(2-pyridyl    O
)    O
thiocarbonate    O
(    O
DPTC    O
)    O
and    O
DMAP    B-Pyridine114692510
forming    O
ester    O
63    O
.    O

However    O
,    O
with    O
the    O
addition    O
of    O
4-dimethylaminopyridine    B-Pyridine114692510
(    O
DMAP    O
)    O
as    O
a    O
catalyst    O
,    O
the    O
reaction    O
can    O
take    O
place    O
at    O
room    O
temperature    O
.    O

The    O
TIPS    O
silyl    O
enol    O
ether    O
1.11    O
was    O
formed    O
by    O
reaction    O
with    O
the    O
triflate    O
TIPSOtf    O
and    O
DBU    O
in    O
DMAP    B-Pyridine114692510
setting    O
the    O
stage    O
for    O
asymmetric    O
dihydroxylation    O
to    O
hydroxyaldehyde    O
1.12    O
.    O

The    O
Steglich    O
esterification    O
is    O
a    O
variation    O
of    O
an    O
esterfication    O
with    O
dicyclohexylcarbodiimide    O
as    O
a    O
coupling    O
reagent    O
and    O
4-dimethylaminopyridine    B-Pyridine114692510
as    O
a    O
catalyst    O
.    O

Chloropyramine    B-Pyridine114692510
is    O
a    O
classical    O
(    O
"    O
old    O
"    O
or    O
first    O
generation    O
)    O
antihistamine    O
drug    O
approved    O
in    O
some    O
Eastern    O
European    O
countries    O
(    O
like    O
Russia    O
)    O
for    O
the    O
treatment    O
of    O
allergic    O
conjunctivitis    O
,    O
allergic    O
rhinitis    O
,    O
bronchial    O
asthma    O
,    O
and    O
other    O
atopic    O
(    O
allergic    O
)    O
conditions    O
.    O

Deoxypyridinoline    B-Pyridine114692510
,    O
also    O
called    O
D-Pyrilinks    B-Pyridine114692510
,    O
Pyrilinks-D    B-Pyridine114692510
,    O
or    O
deoxyPYD    B-Pyridine114692510
,    O
is    O
one    O
of    O
two    O
pyridinium    O
cross    O
-    O
links    O
that    O
provide    O
structural    O
stiffness    O
to    O
type    O
I    O
collagen    O
found    O
in    O
bones    O
.    O

Cephapirin    B-Pyridine114692510

Emoxypine    B-Pyridine114692510
(    O
2-ethyl-6-methyl-3-hydroxypyridine    O
)    O
,    O
also    O
known    O
as    O
Mexidol    B-Pyridine114692510
or    O
Mexifin    B-Pyridine114692510
when    O
used    O
as    O
the    O
succinate    O
salt    O
,    O
is    O
an    O
antioxidant    O
manufactured    O
in    O
Russia    O
by    O
Pharmasoft    O
Pharmaceuticals    O
.    O

Niludipine    B-Pyridine114692510
is    O
a    O
calcium    O
channel    O
blocker    O
.    O

The    O
European    O
Commission    O
decided    O
to    O
suspend    O
use    O
of    O
the    O
company    O
's    O
insecticide    O
Cruiser    O
(    O
thiamethoxam    B-Pyridine114692510
,    O
TMX    O
)    O
on    O
crops    O
pollinated    O
by    O
bees    O
.    O

In    O
contrast    O
to    O
neonicotinoid    B-Pyridine114692510
such    O
as    O
acetamiprid    B-Pyridine114692510
,    O
clothianidin    B-Pyridine114692510
,    O
imidacloprid    B-Pyridine114692510
,    O
and    O
thiamethoxam    B-Pyridine114692510
,    O
which    O
are    O
absorbed    O
through    O
the    O
skin    O
to    O
some    O
extent    O
,    O
fipronil    O
is    O
not    O
absorbed    O
substantially    O
through    O
the    O
skin    O
.    O

The    O
European    O
Food    O
Safety    O
Authority    O
ruled    O
that    O
three    O
neonicotinoid    B-Pyridine114692510
pesticides    O
(    O
clothianidin    B-Pyridine114692510
,    O
imidacloprid    B-Pyridine114692510
,    O
and    O
thiamethoxam    B-Pyridine114692510
)    O
presented    O
a    O
high    O
risk    O
for    O
bees    O
.    O

These    O
include    O
atropine    O
,    O
cyclopentolate    O
,    O
homatropine    O
,    O
scopolamine    O
and    O
tropicamide    B-Pyridine114692510
.    O

In    O
an    O
early    O
study    O
on    O
the    O
stable    O
isotope    O
compositions    O
of    O
tropicamide    B-Pyridine114692510
,    O
hydrocortisone    O
,    O
quinine    O
and    O
tryptophan    O
,    O
carbon    O
,    O
nitrogen    O
,    O
oxygen    O
and    O
hydrogen    O
stable    O
isotopes    O
were    O
analyzed    O
by    O
EA    O
-    O
IRMS    O
and    O
clear    O
distinctions    O
were    O
able    O
to    O
be    O
made    O
between    O
manufacturers    O
and    O
even    O
batches    O
of    O
the    O
drugs    O
based    O
on    O
their    O
isotope    O
signatures    O
.    O

Tropicamide    B-Pyridine114692510

Sulfur    B-Pyridine114692510
trioxide    I-Pyridine114692510
pyridine    I-Pyridine114692510
complex    I-Pyridine114692510
,    O
SO3(py    O
)    O

dexchlorpheniramine    B-Pyridine114692510
maleate    I-Pyridine114692510

dexchlorpheniramine    B-Pyridine114692510
(    O
INN    O
)    O

3-Aminopyridine    B-Pyridine114692510

xanomeline    B-Pyridine114692510

Thenyldiamine    B-Pyridine114692510
is    O
an    O
antihistamine    O
and    O
anticholinergic    O
.    O

Six    O
isomers    O
of    O
bipyridine    O
exist    O
,    O
but    O
two    O
isomers    O
are    O
prominent    O
:    O
2,2'-bipyridine    B-Pyridine114692510
is    O
a    O
popular    O
ligand    O
in    O
coordination    O
chemistry    O
and    O
4,4'-bipyridine    O
is    O
a    O
precursor    O
to    O
the    O
herbicide    O
paraquat    O
.    O

Among    O
these    O
compounds    O
,    O
2,2’-diboratabiphenyl    O
is    O
the    O
first    O
bidentate    O
Lewis    O
acid    O
based    O
on    O
a    O
borabenzene    O
framework    O
,    O
so    O
it    O
is    O
regarded    O
as    O
a    O
Lewis    O
acid    O
analogue    O
of    O
2,2’-bipyridine    B-Pyridine114692510
,    O
a    O
common    O
bidentate    O
ligand    O
.    O

The    O
interaction    O
of    O
the    O
Grignard    O
reagent    O
with    O
phenanthroline    B-Pyridine114692510
or    O
2,2'-bipyridine    B-Pyridine114692510
causes    O
a    O
color    O
change    O
.    O

For    O
the    O
[    O
bipy    B-Pyridine114692510
+    O
pair    O
,    O
self    O
exchange    O
proceeds    O
at    O
109    O
M−1s−1    O
.    O

Pyridine    O
is    O
oxidatively    O
coupled    O
to    O
2,2'-bipyridine    B-Pyridine114692510
over    O
a    O
heated    O
Raney    O
nickel    O
catalyst    O
.    O

pirbuterol    B-Pyridine114692510

Pirbuterol    B-Pyridine114692510

Piclamilast    B-Pyridine114692510

PSN-632,408    B-Pyridine114692510

A-366,833    B-Pyridine114692510
is    O
a    O
drug    O
developed    O
by    O
Abbott    O
,    O
which    O
acts    O
as    O
an    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
selective    O
for    O
the    O
α4β2    O
subtype    O
,    O
and    O
has    O
been    O
researched    O
for    O
use    O
as    O
an    O
analgesic    O
,    O
although    O
it    O
has    O
not    O
passed    O
clinical    O
trials    O
.    O

Image    O
:    O
4-Amino-3,5,6-trichloropicolinic    B-Pyridine114692510
acid    I-Pyridine114692510
(    O
tordon    O
or    O
picloram    O
)    O
;    O
active    O
herbicide    O

A    O
systemic    O
herbicide    O
,    O
for    O
example    O
,    O
glyphosate    O
,    O
triclopyr    B-Pyridine114692510
,    O
or    O
picloram    B-Pyridine114692510
,    O
can    O
be    O
applied    O
directly    O
on    O
cut    O
stems    O
,    O
which    O
is    O
an    O
effective    O
means    O
of    O
transporting    O
the    O
herbicide    O
into    O
the    O
kudzu    O
's    O
extensive    O
root    O
system    O
.    O

Chemical    O
control    O
can    O
be    O
achieved    O
with    O
a    O
variety    O
of    O
products    O
including    O
:    O
Clopyralid    B-Pyridine114692510
,    O
glyphosate    O
,    O
Diquat    O
,    O
Picloram    B-Pyridine114692510
,    O
and    O
2    O
,    O
4-D    O
ester    O
.    O

PD    B-Pyridine114692510
144418    I-Pyridine114692510

GTS-21    B-Pyridine114692510
(    O
DMBX-A    B-Pyridine114692510
)    O
is    O
a    O
derivative    O
of    O
the    O
natural    O
product    O
anabaseine    O
that    O
acts    O
as    O
a    O
partial    O
agonist    O
at    O
neural    O
nicotinic    O
acetylcholine    O
receptors    O
.    O

A    O
lot    O
of    O
quinolone    O
antibiotic    O
structures    O
such    O
as    O
Rosoxacin    B-Pyridine114692510
,    O
Oxolinic    O
acid    O
,    O
Droxacin    O
,    O
etc    O
.    O

Nilotinib    B-Pyridine114692510
is    O
a    O
phenylamino    O
-    O
pyrimidine    O
derivative    O
that    O
is    O
structurally    O
related    O
to    O
imatinib    O
.    O

Crystal    O
structure    O
of    O
Abl    O
kinase    O
domain    O
(    O
blue    O
)    O
in    O
complex    O
with    O
nilotinib    B-Pyridine114692510
(    O
red    O
)    O
.    O

In    O
those    O
cases    O
other    O
inhibitors    O
such    O
as    O
dasatinib    O
and    O
nilotinib    B-Pyridine114692510
can    O
be    O
used    O
.    O

The    O
volatile    O
chemicals    O
that    O
are    O
currently    O
known    O
to    O
cause    O
these    O
behavioral    O
effects    O
in    O
cats    O
are    O
actinidine    B-Pyridine114692510
from    O
"    O
Valeriana    O
officinalis    O
"    O
,    O
nepetalactone    O
from    O
"    O
Nepeta    O
cataria    O
"    O
(    O
catnip    O
)    O
,    O
dihydronepetalactone    O
,    O
neonepetalactone    O
,    O
isodihydronepetalactone    O
,    O
epinepetalactone    O
,    O
boschnialactone    O
,    O
boschniakine    O
,    O
dihydroactinidiolide    O
,    O
actinidiolide    O
,    O
iridomyrmecin    O
,    O
(    O
−)-mitsugashiwalactone    O
,    O
and    O
onikulactone    O
.    O

TCS-OX2-29    B-Pyridine114692510
is    O
an    O
orexin    O
antagonist    O
.    O

ipidacrine    B-Pyridine114692510
(    O
INN    O
)    O

Due    O
to    O
its    O
broad    O
scope    O
,    O
the    O
Kröhnke    O
method    O
has    O
seen    O
wide    O
applicability    O
to    O
for    O
the    O
synthesis    O
of    O
bipyridine    B-Pyridine114692510
(    O
16    O
)    O
,    O
terpyridine    B-Pyridine114692510
(    O
17    O
)    O
,    O
quaterpyridines    O
(    O
18    O
)    O
and    O
even    O
up    O
to    O
septipyridines    O
(    O
19    O
)    O
as    O
shown    O
below    O
.    O

Terpyridine    B-Pyridine114692510

Isonicotinamide    O
(    O
pyridine-4-carboxamide    O
)    O
is    O
the    O
amide    O
form    O
of    O
isonicotinic    B-Pyridine114692510
acid    I-Pyridine114692510
.    O

#    O
It    O
is    O
also    O
used    O
to    O
prepare    O
pinacidil    B-Pyridine114692510
,    O
as    O
well    O
as    O
naminidil    O
.    O

Examples    O
include    O
Sotalol    O
,    O
ibutilide    O
,    O
sematilide    O
,    O
Dronedarone    O
,    O
Dofetilide    O
,    O
E-4031    B-Pyridine114692510
,    O
and    O
Bitopertin    O
.    O

Droxicam    B-Pyridine114692510

Some    O
common    O
pharmacological    O
inhibitors    O
of    O
P    O
-    O
glycoprotein    O
include    O
:    O
amiodarone    O
,    O
clarithromycin    O
,    O
ciclosporin    O
,    O
colchicine    O
,    O
diltiazem    O
,    O
erythromycin    O
,    O
felodipine    B-Pyridine114692510
,    O
lansoprazole    O
,    O
omeprazole    O
and    O
other    O
proton    O
-    O
pump    O
inhibitors    O
,    O
nifedipine    O
,    O
paroxetine    O
,    O
sertraline    O
,    O
quinidine    O
,    O
tamoxifen    O
and    O
verapamil    O
.    O

felodipine    B-Pyridine114692510

Felodipine    B-Pyridine114692510
is    O
a    O
medication    O
of    O
the    O
calcium    O
channel    O
blocker    O
type    O
which    O
is    O
used    O
to    O
treat    O
high    O
blood    O
pressure    O
.    O

bromazepam    B-Pyridine114692510

Other    O
classical    O
benzodiazepines    O
include    O
chlordiazepoxide    O
,    O
clonazepam    O
,    O
lorazepam    O
,    O
oxazepam    O
,    O
nitrazepam    O
,    O
temazepam    O
,    O
flurazepam    O
,    O
bromazepam    B-Pyridine114692510
,    O
and    O
clorazepate    O
.    O

Benzodiazepines    O
with    O
a    O
half    O
-    O
life    O
of    O
less    O
than    O
24    O
hours    O
include    O
alprazolam    O
,    O
bromazepam    B-Pyridine114692510
,    O
brotizolam    O
,    O
flunitrazepam    O
,    O
loprazolam    O
,    O
lorazepam    O
,    O
lormetazepam    O
,    O
midazolam    O
,    O
nitrazepam    O
,    O
oxazepam    O
,    O
and    O
temazepam    O
.    O

4-Deoxypyridoxine    B-Pyridine114692510

MTEP    B-Pyridine114692510
:    O
more    O
potent    O
than    O
MPEP    O

Roxindole    B-Pyridine114692510
(    O
only    O
at    O
the    O
D2    O
autoreceptors    O
)    O

Diphenyl-2-pyridylmethane    B-Pyridine114692510

The    O
CRH-1    O
receptor    O
antagonist    O
pexacerfont    B-Pyridine114692510
is    O
currently    O
under    O

Dimethyl-4β-(2-naphthyl)piperidine-3β-carboxylate    O
(    O
"    O
'    O
DMNPC    O
)    O
is    O
a    O
piperidine    O
based    O
stimulant    O
drug    O
which    O
is    O
synthesised    O
from    O
arecoline    B-Pyridine114692510
.    O

The    O
total    O
synthesis    O
of    O
a    O
number    O
of    O
natural    O
alkaloids    O
–    O
pilocarpine    O
,    O
pilozinin    O
,    O
alkaloids    O
of    O
propane    O
series    O
(    O
tropine    O
,    O
cocaine    O
)    O
,    O
arecoline    B-Pyridine114692510
,    O
eserine    O
,    O
emetine    O
,    O
psyhotrine    O
,    O
emataliine    O
,    O
cinchonamine    O
,    O
tubocurarine    O
and    O
other    O
alkaloids    O
of    O
curare    O
(    O
magnolin    O
,    O
magnolamine    O
,    O
dauricine    O
)    O
.    O

The    O
major    O
psychoactive    O
ingredients    O
–    O
arecoline    B-Pyridine114692510
(    O
a    O
muscarinic    O
receptor    O
partial    O
agonist    O
)    O
and    O
arecaidine    O
(    O
a    O
GABA    O
reuptake    O
inhibitor    O
)    O
–    O
are    O
responsible    O
for    O
the    O
euphoric    O
effect    O
.    O

nimodipine    B-Pyridine114692510

Nimodipine    B-Pyridine114692510

Verapamil    O
,    O
nimodipine    B-Pyridine114692510
,    O
and    O
other    O
calcium    O
channel    O
blockers    O
may    O
help    O
reduce    O
the    O
intensity    O
and    O
frequency    O
of    O
the    O
headaches    O
.    O

"    O
Ueber    O
ein    O
neues    O
Collidin    O
und    O
eine    O
Pipecolincarbonsäure    O
"    O
,    O
1893    O
–    O
About    O
a    O
new    O
collidine    B-Pyridine114692510
and    O
a    O
pipercolic    O
carboxylic    O
acid    O
.    O

2,6-Pyridinedicarbothioic    B-Pyridine114692510
acid    I-Pyridine114692510

;    O
Chlorpheniramine    B-Pyridine114692510
(    O
maleate    O
)    O

Sometimes    O
a    O
third    O
active    O
ingredient    O
,    O
such    O
as    O
ascorbic    O
acid    O
,    O
caffeine    O
,    O
chlorpheniramine    B-Pyridine114692510
maleate    I-Pyridine114692510
,    O
or    O
guaifenesin    O
is    O
added    O
to    O
this    O
combination    O
.    O

These    O
can    O
include    O
codeine    O
as    O
co    O
-    O
codamol    O
,    O
dextromethorphan    O
,    O
methocarbamol    O
,    O
guaifenesin    O
,    O
psuedoephedrine    O
,    O
caffeine    O
,    O
diphenhydramine    O
,    O
chlorpheniramine    B-Pyridine114692510
and    O
phenylephrine    O
.    O

A    O
form    O
that    O
contains    O
dextromethorphan    O
,    O
pseudoephedrine    O
,    O
acetaminophen    O
,    O
and    O
chlorpheniramine    B-Pyridine114692510
,    O
is    O
sold    O
as    O
Cotylenol    O
.    O

Many    O
drugs    O
that    O
contain    O
amines    O
are    O
provided    O
as    O
the    O
maleate    O
acid    O
salt    O
,    O
e.g.    O
carfenazine    O
,    O
chlorpheniramine    B-Pyridine114692510
,    O
pyrilamine    B-Pyridine114692510
,    O
methylergonovine    O
,    O
and    O
thiethylperazine    O
.    O

These    O
medicines    O
included    O
the    O
antidepressants    O
Citalopram    O
and    O
Duloxetine    O
,    O
as    O
well    O
as    O
the    O
antitussive    O
Dextromethorphan    O
and    O
the    O
antihistamines    O
Diphenhydramine    O
and    O
Chlorpheniramine    B-Pyridine114692510
.    O

Chlorpheniramine    B-Pyridine114692510
(    O
Chlor    O
-    O
Trimeton    O
)    O

"    O
Panadol    O
Cold    O
and    O
Catarrh    O
"    O
contains    O
three    O
active    O
ingredients    O
:    O
paracetamol    O
,    O
phenylephrine    O
hydrochloride    O
as    O
a    O
nasal    O
decongestant    O
,    O
and    O
chlorpheniramine    B-Pyridine114692510
maleate    I-Pyridine114692510
to    O
prevent    O
certain    O
allergies    O
.    O

Chlorpheniramine    B-Pyridine114692510
is    O
an    O
antihistamine    O
that    O
helps    O
to    O
relieve    O
allergic    O
disorders    O
due    O
to    O
cold    O
,    O
hay    O
fever    O
,    O
itchy    O
skin    O
,    O
insect    O
bites    O
and    O
stings    O
.    O

Tenatoprazole    B-Pyridine114692510

For    O
example    O
,    O
fenitrothion    O
,    O
malathion    O
,    O
acetamiprid    B-Pyridine114692510
,    O
and    O
thiacloprid    B-Pyridine114692510
.    O

Dexlansoprazole    B-Pyridine114692510
(    O
brand    O
names    O
:    O
Kapidex    O
,    O
Dexilant    O
)    O

vorapaxar    B-Pyridine114692510
(    O
USAN    O
,    O
INN    O
)    O

Hycamtin    B-Pyridine114692510

Hycamtin    B-Pyridine114692510
(    O
GlaxoSmithKline    O
)    O

Some    O
cancer    O
treatments    O
like    O
bexarotene    O
,    O
busulfan    O
,    O
chlorambucil    O
,    O
estramustine    O
,    O
etoposide    O
,    O
flutamide    O
,    O
idarubicin    O
,    O
ifosfamide    O
,    O
irinotecan    O
,    O
ixabepilone    O
,    O
letrozole    O
,    O
lomustine    O
,    O
megestrol    O
,    O
mitomycin    O
,    O
mitoxantrone    O
,    O
paclitaxel    O
,    O
procarbazine    O
,    O
tamoxifen    O
,    O
topotecan    B-Pyridine114692510

Some    O
newer    O
regimens    O
include    O
topoisomerase    O
I    O
inhibitors    O
(    O
topotecan    B-Pyridine114692510
and    O
irinotecan    O
)    O
in    O
induction    O
which    O
have    O
been    O
found    O
to    O
be    O
effective    O
against    O
recurrent    O
disease    O
.    O

Liposomal    O
lurtotecan    O
was    O
in    O
clinical    O
trials    O
as    O
a    O
treatment    O
for    O
topotecan    B-Pyridine114692510
-    O
resistant    O
ovarian    O
cancer    O
,    O
but    O
was    O
discontinued    O
.    O

,    O
the    O
sGC    O
activators    O
cinaciguat    O
and    O
riociguat    B-Pyridine114692510
were    O
undergoing    O
clinical    O
trials    O
for    O
the    O
treatment    O
of    O
PAH    O
.    O

Fluroxypyr    B-Pyridine114692510
is    O
an    O
herbicide    O
in    O
the    O
class    O
of    O
synthetic    O
auxins    O
.    O

Alvameline    B-Pyridine114692510

The    O
day    O
before    O
the    O
colonoscopy    O
,    O
the    O
patient    O
is    O
either    O
given    O
a    O
laxative    O
preparation    O
(    O
such    O
as    O
Picosalax    B-Pyridine114692510
,    O
Bisacodyl    B-Pyridine114692510
,    O
phospho    O
soda    O
,    O
sodium    B-Pyridine114692510
picosulfate    I-Pyridine114692510
,    O
or    O
sodium    O
phosphate    O
and/or    O
magnesium    O
citrate    O
)    O
and    O
large    O
quantities    O
of    O
fluid    O
,    O
or    O
whole    O
bowel    O
irrigation    O
is    O
performed    O
using    O
a    O
solution    O
of    O
polyethylene    O
glycol    O
and    O
electrolytes    O
.    O

gapicomine    B-Pyridine114692510
(    O
INN    O
)    O

:    O
C10AD03    O
Nicofuranose    B-Pyridine114692510


